{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:22Z","timestamp":1792093762066,"version":"4.4.0"},"reference-count":663,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004697","name":"Hamadan University of Medical Sciences","doi-asserted-by":"publisher","award":["49002"],"award-info":[{"award-number":["49002"]}],"id":[{"id":"10.13039\/501100004697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.mam.2026.101521","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:36:42Z","timestamp":1792039002000},"page":"101521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-1397","authenticated-orcid":false,"given":"Neda","family":"Shakour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Hadizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1139\/cjpp-2020-0049","article-title":"Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice","volume":"99","author":"Abd Elmaaboud","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.15430\/JCP.24.012","article-title":"Risk of incident cancer in veterans with diabetes who use metformin Versus sulfonylureas","volume":"29","author":"Abdallah","year":"2024","journal-title":"J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib3","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202302461RR","article-title":"Linagliptin, a DPP-4 inhibitor, activates AMPK\/FOXO3a and suppresses NF\u03baB to mitigate the debilitating effects of diethylnitrosamine exposure in rat liver: novel mechanistic insights","volume":"38","author":"Abdelhady","year":"2024","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib4","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202302461RR","article-title":"Linagliptin, a DPP\u20104 inhibitor, activates AMPK\/FOXO3a and suppresses NF\u03baB to mitigate the debilitating effects of diethylnitrosamine exposure in rat liver: novel mechanistic insights","volume":"38","author":"Abdelhady","year":"2024","journal-title":"FASEB J. : Off. Publ. Feder. Am. Soc. Experiment. Biol."},{"key":"10.1016\/j.mam.2026.101521_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112455","article-title":"Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application","volume":"145","author":"Abdelhamid","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mam.2026.101521_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112455","article-title":"Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application","volume":"145","author":"Abdelhamid","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"17","key":"10.1016\/j.mam.2026.101521_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713353","article-title":"The impact of metformin on tumor-infiltrated immune cells: preclinical and clinical studies","volume":"24","author":"Abdelmoneim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s00066-015-0884-5","article-title":"Metformin influences progression in diabetic glioblastoma patients","volume":"191","author":"Adeberg","year":"2015","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.mam.2026.101521_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.30683\/1929-2279.2025.14.02","article-title":"Synergistic antiproliferative effect of linagliptin-metformin combination on the growth of Hela cancer cell line","volume":"14","author":"Ahmed","year":"2025","journal-title":"J. Cancer Res. Updates"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/14728210802584126","article-title":"Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes","volume":"13","author":"Ahr\u00e9n","year":"2008","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdiacomp.2012.03.013","article-title":"Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates \u03b2-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes","volume":"26","author":"Akarte","year":"2012","journal-title":"J. Diabetes Complicat."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib12","article-title":"Anticancer and antioxidant effects of sitagliptin and linagliptin against lung cancer cell lines (an In vitro Study)","volume":"8","author":"Al Khafaji","year":"2024","journal-title":"Tropical J. Nat. Prod. Res."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib13","doi-asserted-by":"crossref","DOI":"10.22317\/jcms.v10i3.1555","article-title":"Synergistic antitumor and apoptotic activity of sitagliptin or linagliptin plus cisplatin against A549 lung cancer cells (an Invitro Study)","volume":"10","author":"Al Khafaji","year":"2024","journal-title":"J. Contemp. Med. Sci."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib14","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s11845-024-03634-4","article-title":"Vitamin B12 deficiency in diabetic patients treated with metformin: a narrative review","volume":"193","author":"Al Zoubi","year":"2024","journal-title":"Ir. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/1559325821995651","article-title":"Anti-proliferative activity of glucagon-like Peptide-1 receptor agonist on obesity-associated breast cancer: the impact on modulating adipokines' expression in adipocytes and cancer cells","volume":"19","author":"Alanteet","year":"2021","journal-title":"Dose Response"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1559325821995651","article-title":"Anti-proliferative activity of glucagon-like peptide-1 receptor agonist on obesity-associated breast cancer: the impact on modulating adipokines' expression in adipocytes and cancer cells","volume":"19","author":"Alanteet","year":"2021","journal-title":"Dose Response : Publ. Int. Hormesis Soc."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib17","article-title":"Overall clinical features of type 2 diabetes mellitus with respect to gender","volume":"15","author":"Ali","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.dsx.2018.08.012","article-title":"Dipeptidyl peptidase-4 inhibitors: anti-diabetic drugs with potential effects on cancer","volume":"13","author":"Almagthali","year":"2019","journal-title":"Diabetes Metabol. Syndr.: Clin. Res. Rev."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2024.102059","article-title":"Pioglitazone enhances cisplatin's impact on triple-negative breast cancer: role of PPAR\u03b3 in cell apoptosis","volume":"32","author":"Alqahtani","year":"2024","journal-title":"Saudi Pharm. J."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2024.102059","article-title":"Pioglitazone enhances cisplatin's impact on triple-negative breast cancer: role of PPAR\u03b3 in cell apoptosis","volume":"32","author":"Alqahtani","year":"2024","journal-title":"Saudi Pharm. J."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib21","article-title":"Pioglitazone enhances cisplatin's impact on triple-negative breast cancer: role of PPAR\u03b3 in cell apoptosis","volume":"32","author":"Alqahtani","year":"2024","journal-title":"Saudi Pharm. J. : SPJ : Off. Publ. Saudi Pharm. Soc."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/biology13050302","article-title":"Metformin: from diabetes to cancer\u2014unveiling molecular mechanisms and therapeutic strategies","volume":"13","author":"Amengual-Cladera","year":"2024","journal-title":"Biology"},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib23","first-page":"14","article-title":"Evaluation of anti cancer effects of DPP-4 inhibitors in colon cancer-an invitro study","volume":"9","author":"Amritha","year":"2015","journal-title":"J. Clin. Diagn. Res. : J. Clin. Diagn. Res."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib24","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v16.i10.110174","article-title":"Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"16","author":"An","year":"2025","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","article-title":"Progress in adjuvant chemotherapy for breast cancer: an overview","volume":"13","author":"Anampa","year":"2015","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13300-016-0211-x","article-title":"Empagliflozin: role in treatment options for patients with type 2 diabetes mellitus","volume":"8","author":"Anderson","year":"2017","journal-title":"Diab. Ther. : Res., Treat. Edu. Diab. Relat. Disord."},{"issue":"1\u20133","key":"10.1016\/j.mam.2026.101521_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.molstruc.2009.02.020","article-title":"Preparation and spectroscopic characterization of metal complexes of gliquidone","volume":"927","author":"Arayne","year":"2009","journal-title":"J. Mol. Struct."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib28","first-page":"645","article-title":"Exploring the synergistic anticancer potential of Linagliptin and esomeprazole in cervical cancer cell line: mechanistic insights into targeting HSPB1, Hsp60","volume":"10","author":"Arean","year":"2025","journal-title":"J. Cancer Biol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib29","first-page":"302","article-title":"Exploring the potential impact of GLP-1 receptor agonists in cancer therapy","volume":"50","author":"Aslam","year":"2023","journal-title":"Minerva Endocrinol."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23764","article-title":"Dulaglutide reduces oxidative DNA damage and hypermethylation in the somatic cells of mice fed a high\u2010energy diet by restoring redox balance, inflammatory responses, and DNA repair gene expressions","volume":"38","author":"Attia","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23764","article-title":"Dulaglutide reduces oxidative DNA damage and hypermethylation in the somatic cells of mice fed a high-energy diet by restoring redox balance, inflammatory responses, and DNA repair gene expressions","volume":"38","author":"Attia","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/dom.14555","article-title":"Sotagliflozin for patients with type 2 diabetes: a systematic review and meta\u2010analysis","volume":"24","author":"Avgerinos","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.mam.2026.101521_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112110","article-title":"Potential mitigating impact of a dipeptidyl peptidase-IV inhibitor, vildagliptin, on oxazolone-induced ulcerative colitis: targeting the role of PI3K\/AKT\/mTOR and AMPK\/Nrf2 signaling pathways","volume":"133","author":"Awad","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s43440-019-00034-9","article-title":"Bisoprolol and linagliptin ameliorated electrical and mechanical isometric myocardial contractions in doxorubicin-induced cardiomyopathy in rats","volume":"72","author":"Aykan","year":"2020","journal-title":"Pharmacol. Rep. : PR"},{"issue":"18","key":"10.1016\/j.mam.2026.101521_bib35","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.3390\/cancers16183224","article-title":"Risk of esophageal and gastric cancer in patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs): a national analysis","volume":"16","author":"Ayoub","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-06494-9","article-title":"Synthesis and swelling studies of modified chitosan smart hydrogels containing alkyl sulfonate anionic pendant groups as microparticles for insulin release","volume":"15","author":"Azimi","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2026.101521_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.15663","article-title":"Metformin: therapeutic profile in the treatment of type 2 diabetes","volume":"26","author":"Bailey","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.mam.2026.101521_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1181312","article-title":"Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial","volume":"14","author":"Bakry","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib39","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s001250051445","article-title":"Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7\u201336 amide) concentrations and improves oral glucose tolerance in obese Zucker rats","volume":"42","author":"Balkan","year":"1999","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","article-title":"TNF-\u03b1 in promotion and progression of cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.mam.2026.101521_bib41","first-page":"253","article-title":"Exploring the role of sodium-glucose cotransporter as a new target for cancer therapy","volume":"25","author":"Bardaweel","year":"2022","journal-title":"J. Pharm. Pharmaceut. Sci."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib42","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ni.3201","article-title":"Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy","volume":"16","author":"Barreira da Silva","year":"2015","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib43","article-title":"Oxidative stress and lipid peroxidation products in cancer progression and therapy","volume":"2012","author":"Barrera","year":"2012","journal-title":"ISRN Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mam.2026.101521_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106039","article-title":"Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials","volume":"175","author":"Benedetti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mam.2026.101521_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106039","article-title":"Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials","volume":"175","author":"Benedetti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mam.2026.101521_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123060","article-title":"An anti-neoplastic tale of metformin through its transport","volume":"357","author":"Bhati","year":"2024","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib48","first-page":"161","article-title":"Evolution of exenatide as a diabetes therapeutic","volume":"9","author":"Bhavsar","year":"2013","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.mam.2026.101521_bib49","series-title":"Bioassay of Tetrachloroethylene for Possible Carcinogenicity","author":"Bioassay","year":"1978"},{"key":"10.1016\/j.mam.2026.101521_bib50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fendo.2018.00446","article-title":"Metformin, an anti-diabetic drug to target leukemia","volume":"9","author":"Biondani","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib51","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib54","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3892\/ol.2015.3554","article-title":"Antitumor action of the peroxisome proliferator-activated receptor-\u03b3 agonist rosiglitazone in hepatocellular carcinoma","volume":"10","author":"Bo","year":"2015","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/EJE-13-0299","article-title":"Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients","volume":"169","author":"Bo","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/EJE-13-0299","article-title":"Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients","volume":"169","author":"Bo","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib56","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1158\/1055-9965.EPI-11-0992-T","article-title":"Use of metformin is not associated with a decreased risk of colorectal cancer: a case\u2013control analysis","volume":"21","author":"Bodmer","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib55","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc09-1791","article-title":"Long-term metformin use is associated with decreased risk of breast cancer","volume":"33","author":"Bodmer","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib57","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-8587(24)00339-5","article-title":"Dissection of type 2 diabetes: a genetic perspective","volume":"13","author":"Bonnefond","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.mam.2026.101521_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119329","article-title":"Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer","volume":"274","author":"Bora","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1055-9965.EPI-10-0817","article-title":"Metformin and incident breast cancer among diabetic women: a population-based case\u2013control study in Denmark","volume":"20","author":"Bosco","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"19","key":"10.1016\/j.mam.2026.101521_bib60","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.3390\/jcm12196195","article-title":"Preventive and therapeutic effect of metformin in head and neck cancer: a concise review","volume":"12","author":"Bouland","year":"2023","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib61","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.29.02.06.dc05-1558","article-title":"Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin","volume":"29","author":"Bowker","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib62","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/cancers14092072","article-title":"Does DPP-IV inhibition offer new avenues for therapeutic intervention in malignant disease?","volume":"14","author":"Busek","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib63","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1210\/en.2014-1722","article-title":"Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents","volume":"156","author":"Byrd","year":"2015","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib64","first-page":"2388","article-title":"Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis","volume":"63","author":"Caderni","year":"2003","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib65","first-page":"709","article-title":"Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study","volume":"27","author":"Calip","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib66","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1345\/aph.17360","article-title":"Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus","volume":"32","author":"Campbell","year":"1998","journal-title":"J Annals Pharmacother."},{"key":"10.1016\/j.mam.2026.101521_bib67","article-title":"Type 2 diabetes and cancer: what is the connection?","author":"Cannata","year":"2010","journal-title":"J. Med.: J. Transl."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib68","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/ijms22020555","article-title":"Disrupting insulin and IGF receptor function in cancer","volume":"22","author":"Cao","year":"2021","journal-title":"J. Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib70","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/aps.2009.119","article-title":"Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPAR\u03b3 signaling pathway","volume":"30","author":"Cao","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib69","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1745-7254.2007.00571.x","article-title":"Upregulation of PTEN involved in rosiglitazone\u2010induced apoptosis in human hepatocellular carcinoma cells 1","volume":"28","author":"Cao","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib71","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","article-title":"Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis","volume":"45","author":"Cao","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib72","first-page":"S277","article-title":"13. Older adults: standards of care in Diabetes\u20142026","volume":"49","author":"Care","year":"2026","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040149","article-title":"Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells","volume":"7","author":"Cerbone","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib74","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.yexcr.2011.02.014","article-title":"Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells","volume":"317","author":"Cerquetti","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib75","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.yexcr.2011.02.014","article-title":"Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells","volume":"317","author":"Cerquetti","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib76","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib78","first-page":"1279","article-title":"Metformin inhibits self-renewal of colorectal cancer stem cells by inhibiting mitochondrial oxidative phosphorylation","volume":"43","author":"Chang","year":"2023","journal-title":"J. South. Med. Univ."},{"key":"10.1016\/j.mam.2026.101521_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2025.06.048","article-title":"Targeting the NRF2 pathway with linagliptin to inhibit human hepatocellular carcinoma growth","author":"Chang","year":"2025","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib77","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tranon.2018.02.012","article-title":"Dose-dependent relationship between metformin and colorectal cancer occurrence among patients with Type 2 diabetes\u2014A nationwide cohort study","volume":"11","author":"Chang","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib80","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.freeradbiomed.2025.06.048","article-title":"Targeting the NRF2 pathway with linagliptin to inhibit human hepatocellular carcinoma growth","volume":"238","author":"Chang","year":"2025","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib81","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib90","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/2211-5463.13499","article-title":"Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps","volume":"14","author":"Chen","year":"2024","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.mam.2026.101521_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173757","article-title":"In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma","volume":"891","author":"Chen","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mam.2026.101521_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215611","article-title":"Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression","volume":"536","author":"Chen","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mam.2026.101521_bib86","volume":"536","author":"Chen","year":"2022"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib83","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gutjnl-2011-301708","article-title":"Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies","volume":"62","author":"Chen","year":"2013","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib91","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12020-024-03942-w","article-title":"Immune checkpoint inhibitors-induced diabetes mellitus","volume":"86","author":"Chen","year":"2024","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib87","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.7150\/thno.66814","article-title":"The peroxisome proliferator-activated receptor agonist rosiglitazone specifically represses tumour metastatic potential in chromatin inaccessibility-mediated FABP4-deficient gastric cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib88","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-022-03842-5","article-title":"Angiotensin-(1\u20137) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-\u03baB and MAPK pathways","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib89","article-title":"Diabetes medications and cancer risk associations: a systematic review and meta-analysis of evidence over the past 10 years","volume":"13","author":"Chen","year":"2023","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0349","article-title":"Advances in research on the anticancer properties and mechanisms of metformin in lung cancer","volume":"85","author":"Chen","year":"2024","journal-title":"Br. J. Hosp. Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib92","first-page":"74","article-title":"Drug repurposing for cancer treatment through global propagation with a greedy algorithm in a multilayer network","volume":"19","author":"Cheng","year":"2022"},{"key":"10.1016\/j.mam.2026.101521_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109641","article-title":"Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo","volume":"349","author":"Chequin","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.mam.2026.101521_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109641","article-title":"Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo","volume":"349","author":"Chequin","year":"2021","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib95","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/djy144","article-title":"Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication","volume":"111","author":"Cheung","year":"2019","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"22","key":"10.1016\/j.mam.2026.101521_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216396","article-title":"Identification of CDK1, PBK, and CHEK1 as an oncogenic signature in glioblastoma: a bioinformatics approach to repurpose dapagliflozin as a therapeutic agent","volume":"24","author":"Chinyama","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26685\/urncst.894","article-title":"Metformin and mitochondrial apoptosis in breast cancer: mechanistic insights and therapeutic implications","volume":"9","author":"Chitre","year":"2025","journal-title":"Undergraduate Res. Nat. Clin. Sci. Technol. J."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib98","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3803\/EnM.2024.1951","article-title":"Glucocorticoid-induced hyperglycemia: a neglected problem","volume":"39","author":"Cho","year":"2024","journal-title":"Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib99","doi-asserted-by":"crossref","first-page":"501","DOI":"10.33549\/physiolres.934618","article-title":"The role of AMPK\/mTOR signaling pathway in anticancer activity of metformin: this paper is dedicated to the 70th anniversary of the founding of physiologia bohemoslovaca (currently Physiological Research)","volume":"70","author":"Chomanicova","year":"2021","journal-title":"Physiol. Res."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/kjm2.12800","article-title":"Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies","volume":"40","author":"Chong","year":"2024","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.mam.2026.101521_bib101","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes\u20142024","volume":"47","author":"Committee","year":"2023","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.mam.2026.101521_bib102","first-page":"S1","article-title":"Introduction and methodology: standards of care in Diabetes\u20142024","volume":"47","author":"Committee","year":"2023","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib103","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1073\/pnas.0631828100","article-title":"Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance","volume":"100","author":"Conarello","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115974","article-title":"Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: an additional anti-tumor effect of the drug","volume":"170","author":"Coperchini","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mam.2026.101521_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115974","article-title":"Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: an additional anti-tumor effect of the drug","volume":"170","author":"Coperchini","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/ph17030396","article-title":"Metformin and breast cancer: current findings and future perspectives from preclinical and clinical studies","volume":"17","author":"Corleto","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.mam.2026.101521_bib107","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S2213-8587(25)00092-0","article-title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","volume":"13","author":"Coskun","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.mam.2026.101521_bib108","series-title":"Sulfonylureas","author":"Costello","year":"2022"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib109","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202406180","article-title":"Type 2 diabetes","volume":"177","author":"Crawford","year":"2024","journal-title":"Ann. Intern. Med."},{"issue":"14","key":"10.1016\/j.mam.2026.101521_bib110","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2165\/11201060-000000000-00000","article-title":"Liraglutide: a review of its use in type 2 diabetes mellitus","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.mam.2026.101521_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1392375","article-title":"GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report","volume":"14","author":"Crowley","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1392375","article-title":"GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report","volume":"14","author":"Crowley","year":"2024","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib113","article-title":"Pharmacological dissection identifies retatrutide overcomes the therapeutic barrier of Obese TNBC treatments through suppressing the interplay between glycosylation and ubiquitylation of YAP","volume":"12","author":"Cui","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202407494","article-title":"Pharmacological dissection identifies retatrutide overcomes the therapeutic barrier of obese TNBC treatments through suppressing the interplay between glycosylation and ubiquitylation of YAP","volume":"12","author":"Cui","year":"2025","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib115","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/ijms22041680","article-title":"Diabetes, antidiabetic medications and cancer risk in type 2 diabetes: focus on SGLT-2 inhibitors","volume":"22","author":"D\u0105browski","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib116","first-page":"418","article-title":"PPAR \u03b3 agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling","volume":"22","author":"Dana","year":"2019","journal-title":"J. Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib117","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cbi.2018.09.019","article-title":"New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers","volume":"296","author":"Dang","year":"2018","journal-title":"Chem. Biol. Interact."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib118","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/1061186X.2020.1844216","article-title":"Combination treatment strategies with a focus on rosiglitazone and adriamycin for insulin resistant liver cancer","volume":"29","author":"Dang","year":"2021","journal-title":"J. Drug Target."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib119","first-page":"85","article-title":"Metformin in the treatment of colorectal cancer and neuroendocrine tumours","volume":"28","author":"Dani\u0142owska","year":"2024","journal-title":"Contemp. Oncol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib120","first-page":"85","article-title":"Metformin in the treatment of colorectal cancer and neuroendocrine tumours","volume":"28","author":"Dani\u0142owska","year":"2024","journal-title":"Contemp. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib121","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0002-9343(96)00353-1","article-title":"An overview of metformin in the treatment of type 2 diabetes mellitus","volume":"102","author":"Davidson","year":"1997","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib122","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/cen.13830","article-title":"The benefits of adding metformin to tamoxifen to protect the endometrium\u2014a randomized placebo\u2010controlled trial","volume":"89","author":"Davis","year":"2018","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib123","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes","volume":"25","author":"De Block","year":"2023","journal-title":"Obes. Metabol."},{"key":"10.1016\/j.mam.2026.101521_bib124","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/VHRM.S4039","article-title":"Potential of liraglutide in the treatment of patients with type 2 diabetes","author":"Deacon","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib125","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.2741\/2799","article-title":"DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes","volume":"13","author":"Deacon","year":"2008","journal-title":"Front. Biosci."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib126","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.mam.2026.101521_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: an update and future directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s43556-024-00204-z","article-title":"Repurposing metabolic regulators: antidiabetic drugs as anticancer agents","volume":"5","author":"Dhas","year":"2024","journal-title":"Mol. Biomed."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11203790-000000000-00000","article-title":"Sitagliptin: a review of its use in the management of type 2 diabetes mellitus","volume":"70","author":"Dhillon","year":"2010","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.mam.2026.101521_bib130","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s40265-015-0473-z","article-title":"Saxagliptin: a review in type 2 diabetes","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib131","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib132","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI131919","article-title":"Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer","volume":"130","author":"Dietrich","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib133","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154754","article-title":"Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling","volume":"133","author":"Ding","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib134","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154754","article-title":"Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling","volume":"133","author":"Ding","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mam.2026.101521_bib135","series-title":"Effect of a Combination Therapy with a CD26-inhibitor and an anti-PD-L1 Antibody on the Mitotic Rate in Lung Cancer","author":"Dobler","year":"2023"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib136","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1478-3231.2010.02223.x","article-title":"Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease","volume":"30","author":"Donadon","year":"2010","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib137","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00280-025-04788-3","article-title":"Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin","volume":"95","author":"Dong","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib138","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1741-7015-9-33","article-title":"Understanding the benefit of metformin use in cancer treatment","volume":"9","author":"Dowling","year":"2011","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib139","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40200-023-01358-3","article-title":"The impact of metformin on survival in diabetic endometrial cancer patients: a retrospective population-based analysis","volume":"23","author":"Drevinskaite","year":"2024","journal-title":"J. Diabetes Metab. Disord."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib140","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.mam.2026.101521_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metabol."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib142","first-page":"1596","article-title":"Is gliclazide associated with a lower obesity-related cancer risk compared to other sulfonylureas?","volume":"29","author":"Du","year":"2020","journal-title":"A Long-term Prospective Cohort Study"},{"issue":"23","key":"10.1016\/j.mam.2026.101521_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.mam.2026.101521_bib144","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in cancer treatment\u2014mechanisms of action and emerging new perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2165\/00003495-197101020-00002","article-title":"Glibenclamide: a review","volume":"1","author":"Editorial","year":"1971","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.mam.2026.101521_bib146","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/1535370216643418","article-title":"Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats","volume":"241","author":"El-Agamy","year":"2016","journal-title":"Exp. Biol. Med."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib147","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/molecules25081937","article-title":"Metabolic-hydroxy and carboxy functionalization of alkyl moieties in drug molecules: prediction of structure influence and pharmacologic activity","volume":"25","author":"El-Haj","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib148","first-page":"308","article-title":"PPAR \u03b3-dependent anti-tumor and immunomodulatory actions of pioglitazone","volume":"12","author":"El-Sisi","year":"2015","journal-title":"J. Immunot."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib149","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib150","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acsptsci.0c00144","article-title":"Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies","volume":"3","author":"Eliaa","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib151","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10528-016-9754-9","article-title":"A metabolic inhibitory cocktail for grave cancers: metformin, pioglitazone and lithium combination in treatment of pancreatic cancer and glioblastoma multiforme","volume":"54","author":"Elmaci","year":"2016","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.mam.2026.101521_bib152","series-title":"Faculty of Pharmacy and Pharmaceutical Sciences","article-title":"Preliminary validation of a computer-based approach to find new lead molecules targeting the oncogenic Forkhead box M1 transcription factor","author":"Elshaikh","year":"2017"},{"key":"10.1016\/j.mam.2026.101521_bib153","series-title":"Preliminary Validation of a Computer-based Approach to Find New Lead Molecules Targeting the Oncogenic Forkhead Box M1 Transcription Factor","author":"Elshaikh","year":"2017"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib154","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13300-013-0024-0","article-title":"Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies","volume":"4","author":"Engel","year":"2013","journal-title":"Diabetes Ther."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/18755992MTA5hMTIy4","article-title":"Stimulation of peroxisome proliferator-activated receptor-gamma (PPAR\u03b3) using pioglitazone decreases the survival of acute promyelocytic leukemia cells through up-regulation of PTEN expression","volume":"21","author":"Esmaeili","year":"2021","journal-title":"Anti-Cancer Agents Med. Chem.-Anti-Cancer Agents)"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib156","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1871520620666200817101533","article-title":"Stimulation of peroxisome proliferator-activated receptor-gamma (PPAR\u03b3) using pioglitazone decreases the survival of acute promyelocytic leukemia cells through Up-Regulation of PTEN expression","volume":"21","author":"Esmaeili","year":"2021","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib157","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12032-014-0015-7","article-title":"Increased expression of phospho-acetyl-coa carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis","volume":"31","author":"Fang","year":"2014","journal-title":"Med. Oncol."},{"issue":"6487","key":"10.1016\/j.mam.2026.101521_bib158","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib159","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: a systematic literature review","volume":"25","author":"Feier","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/j.1875-9114.1985.tb03404.x","article-title":"Glyburide: a second\u2010generation sulfonylurea hypoglycemic agent: history, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects","volume":"5","author":"Feldman","year":"1985","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib161","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/diab.36.10.1130","article-title":"Effects of tolazamide and exogenous insulin on pattern of postprandial carbohydrate metabolism in patients with non-insulin-dependent diabetes mellitus: results of randomized crossover trial","volume":"36","author":"Firth","year":"1987","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.mam.2026.101521_bib162","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.1026","article-title":"OR19-06 safety and effectiveness of sulfonylureas for pancreas-cancer induced metabolic dysregulation","volume":"9","author":"Flory","year":"2025","journal-title":"J. Endocr. Soc."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib163","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib164","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00019053-200018030-00008","article-title":"Glipizide: a review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus","volume":"18","author":"Foster","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.mam.2026.101521_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107354","article-title":"Vildagliptin attenuates acetic acid-induced colitis in rats via targeting PI3K\/Akt\/NF\u03baB, Nrf2 and CREB signaling pathways and the expression of lncRNA IFNG-AS1 and miR-146a","volume":"92","author":"Fouad","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib166","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071583","article-title":"Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review","volume":"8","author":"Franciosi","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib167","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1245\/s10434-015-5028-8","article-title":"Metformin increases overall survival in patients with diabetes undergoing surgery for colorectal cancer","volume":"23","author":"Fransgaard","year":"2016","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib168","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6086265","article-title":"Rosiglitazone alleviates mechanical allodynia of rats with bone cancer pain through the activation of PPAR-\u03b3 to inhibit the NF-\u03baB\/NLRP3 inflammatory axis in spinal cord neurons","volume":"2021","author":"Fu","year":"2021","journal-title":"PPAR Res."},{"key":"10.1016\/j.mam.2026.101521_bib169","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/DMSO.S171503","article-title":"Is there an association between liraglutide use and female breast cancer in a real-world setting?","volume":"11","author":"Funch","year":"2018","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.mam.2026.101521_bib170","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2147\/DMSO.S305496","article-title":"Risk of thyroid cancer associated with use of liraglutide and other antidiabetic drugs in a US commercially insured population","author":"Funch","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib171","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.3390\/ijms25074083","article-title":"Metformin: a dual-role player in cancer treatment and prevention","volume":"25","author":"Galal","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.mam.2026.101521_bib172","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib173","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/gut.2003.031997","article-title":"Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR\u03b3 independent mechanisms","volume":"53","author":"Galli","year":"2004","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib174","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2007.3.2.203","article-title":"Review of sitagliptin phosphate: a novel treatment for type 2 diabetes","volume":"3","author":"Gallwitz","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib175","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/13543784.2017.1333104","article-title":"Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk","volume":"26","author":"Gao","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib176","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/13543784.2017.1333104","article-title":"Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk","volume":"26","author":"Gao","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.mam.2026.101521_bib177","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3389\/fonc.2020.01563","article-title":"Matrix stiffness-upregulated microRNA-17-5p attenuates the intervention effects of metformin on HCC invasion and metastasis by targeting the PTEN\/PI3K\/Akt pathway","volume":"10","author":"Gao","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib179","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1463-1326.2002.00211.x","article-title":"Simultaneous glyburide\/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes","volume":"4","author":"Garber","year":"2002","journal-title":"Obes. Metabol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib178","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/13543784.17.1.105","article-title":"Update: vildagliptin for the treatment of Type 2 diabetes","volume":"17","author":"Garber","year":"2008","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2006.06.026","article-title":"The PPAR-\u03b3 agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells","volume":"192","author":"Gensch","year":"2007","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib181","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/0008-5472.CAN-05-1245","article-title":"The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices","volume":"66","author":"Ghersi","year":"2006","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib182","first-page":"207","article-title":"Diabetes and cancer: a consensus report","volume":"60","author":"Giovannucci","year":"2010","journal-title":"CA Cancer J. Clin."},{"issue":"20","key":"10.1016\/j.mam.2026.101521_bib183","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1158\/1078-0432.CCR-08-1128","article-title":"Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin","volume":"14","author":"Girnun","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"6_Supplement","key":"10.1016\/j.mam.2026.101521_bib184","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-2189","article-title":"Tirzepatide mitigates obesity-associated metabolic dysregulation and tumor progression in a mouse model of triple-negative breast cancer","volume":"84","author":"Glenny","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000048843","article-title":"Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1\/cip1","volume":"64","author":"G\u00f6ke","year":"2001","journal-title":"Digestion"},{"issue":"20","key":"10.1016\/j.mam.2026.101521_bib186","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of metformin vs placebo on invasive disease\u2013free survival in patients with breast cancer: the MA. 32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib187","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00280-010-1294-0","article-title":"Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids","volume":"67","author":"Gottfried","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"20","key":"10.1016\/j.mam.2026.101521_bib188","first-page":"4262","article-title":"The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation","volume":"116","author":"Green","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib189","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"650","key":"10.1016\/j.mam.2026.101521_bib191","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3248","article-title":"CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia","volume":"14","author":"Grey","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib192","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.trecan.2017.10.003","article-title":"Mitochondrial transfer in the leukemia microenvironment","volume":"3","author":"Griessinger","year":"2017","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib193","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.7314\/APJCP.2014.15.11.4405","article-title":"Oxidative stress and antioxidants in disease and cancer: a review","volume":"15","author":"Gupta","year":"2014","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.mam.2026.101521_bib194","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1455492","article-title":"Metformin and its potential influence on cell fate decision between apoptosis and senescence in cancer, with a special emphasis on glioblastoma","volume":"14","author":"Hajimohammadebrahim-Ketabforoush","year":"2024","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib195","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/ph17030299","article-title":"Implications of NLRP3 suppression using glibenclamide and miR-223 against colorectal cancer","volume":"17","author":"Hamza","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib196","first-page":"299","article-title":"Implications of NLRP3 suppression using glibenclamide and miR-223 against colorectal","volume":"17","author":"Hamza","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib198","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1055-9965.EPI-15-1008","article-title":"Association between metformin use and mortality after cervical cancer in older women with diabetes","volume":"25","author":"Han","year":"2016","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib197","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/1535-7163.MCT-05-0347","article-title":"Rosiglitazone suppresses human lung carcinoma cell growth through PPAR\u03b3-dependent and PPAR\u03b3-independent signal pathways","volume":"5","author":"Han","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib199","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib200","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/IGC.0000000000000855","article-title":"The effect of metformin on oncological outcomes in patients with cervical cancer with type 2 diabetes mellitus","volume":"27","author":"Hanprasertpong","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib201","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-50328-5","article-title":"Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis","volume":"13","author":"Hansen","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib202","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-50328-5","article-title":"Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis","volume":"13","author":"Hansen","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib203","first-page":"34","article-title":"Ertugliflozin, a SGLT-2 inhibitor, guards against thioacetamide-induced liver fibrosis: the Nrf2\/HO-1 and TLR4\/TGF-\u03b21 pathways","volume":"10","author":"Hassan","year":"2025","journal-title":"J. Appl. Veter. Sci."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib204","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.2741\/2787","article-title":"The role of CD26\/dipeptidyl peptidase IV in cancer","volume":"13","author":"Havre","year":"2008","journal-title":"Front. Biosci."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib206","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12032-020-01419-0","article-title":"The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2\/HO1 pathway","volume":"37","author":"He","year":"2020","journal-title":"Med. Oncol."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib207","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12032-020-01419-0","article-title":"The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2\/HO1 pathway","volume":"37","author":"He","year":"2020","journal-title":"Med. Oncol."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib208","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1089\/thy.2022.0317","article-title":"Dipeptidyl peptidase-4 stabilizes integrin \u03b14\u03b21 complex to promote thyroid cancer cell metastasis by activating transforming growth factor-beta signaling pathway","volume":"32","author":"He","year":"2022","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib205","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002749","article-title":"Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a meta-analysis","volume":"95","author":"He","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.mam.2026.101521_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172598","article-title":"Sulfonylurea derivatives and cancer, friend or foe?","volume":"861","author":"Hendriks","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12863-022-01086-2","article-title":"Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy","volume":"23","author":"Hermawan","year":"2022","journal-title":"BMC Genomic Data"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib211","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1210\/jc.2018-01455","article-title":"Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the solution?","volume":"104","author":"Herrera-Mart\u00ednez","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib212","first-page":"26","article-title":"Trp53R172H and kmsg12d cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"129","author":"Hingorani","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib213","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","article-title":"Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth","volume":"20","author":"Hollande","year":"2019","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib214","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s42255-024-01113-9","article-title":"GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management","volume":"6","author":"Holst","year":"2024","journal-title":"Nat. Metab."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib215","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10549-019-05185-0","article-title":"Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes","volume":"175","author":"Hosio","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mam.2026.101521_bib216","series-title":"A Review on Potential Anticancer Properties of Antidiabetic Drugs: Metformin and Sulfonylureas","author":"Hossain","year":"2024"},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib217","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40264-013-0080-4","article-title":"Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case\u2013control study","volume":"36","author":"Hsiao","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.mam.2026.101521_bib218","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.711723","article-title":"Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: a nationwide study in Taiwan","volume":"9","author":"Hsu","year":"2021","journal-title":"Front. Public Health"},{"issue":"16","key":"10.1016\/j.mam.2026.101521_bib219","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/14656566.2018.1525360","article-title":"Ertugliflozin as a monotherapy for the treatment of type 2 diabetes","volume":"19","author":"Hu","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.mam.2026.101521_bib221","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.mam.2026.101521_bib220","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.suronc.2020.09.023","article-title":"Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: a cohort study with propensity score analyses","volume":"35","author":"Hu","year":"2020","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib224","article-title":"Tirzepatide inhibits tumor growth in mice with diet-induced obesity","author":"Huang","year":"2023","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib222","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-020-01213-6","article-title":"Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p\/snail\/DPP4 axis","volume":"19","author":"Huang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib223","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","article-title":"The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib225","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3892\/ijo.2014.2408","article-title":"Evaluation of \u03942-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: evidence of drug treatment association with autophagy and activation of the Nrf2\/Keap1 pathway","volume":"45","author":"Huber","year":"2014","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib226","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","article-title":"Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced \u03b2-catenin activation","volume":"10","author":"Hung","year":"2019","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib227","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.clinthera.2006.05.006","article-title":"Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus","volume":"28","author":"Iltz","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.mam.2026.101521_bib228","first-page":"1097","article-title":"Fluid retention versus cardio protection: rethinking pioglitazone","volume":"10","author":"Imran","year":"2026","journal-title":"Ann. Med. Surg."},{"issue":"1\u20133","key":"10.1016\/j.mam.2026.101521_bib229","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejphar.2012.07.030","article-title":"Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in Non-obese type 2 diabetic Goto-Kakizaki rats","volume":"691","author":"Inaba","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mam.2026.101521_bib230","series-title":"Pubchem Compound Summary","author":"Information","year":"2021"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib231","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10822-025-00646-9","article-title":"Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets","volume":"39","author":"Inglot","year":"2025","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.mam.2026.101521_bib232","doi-asserted-by":"crossref","first-page":"253","DOI":"10.18433\/jpps32879","article-title":"Exploring the role of sodium-glucose cotransporter as a new target for cancer therapy","volume":"25","author":"Issa","year":"2022","journal-title":"Pharm. Pharm. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib233","doi-asserted-by":"crossref","DOI":"10.2174\/0115680266317788241121100259","article-title":"Combating drug resistance in lung cancer: exploring the synergistic potential of metformin and cisplatin in a novel combination therapy; A systematic review","volume":"25","author":"Jafarzadeh","year":"2025","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.mam.2026.101521_bib234","article-title":"Anti-cancer effects of sitagliptin, vildagliptin, and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation","volume":"12","author":"Jaiswal","year":"2022","journal-title":"Biocell"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib235","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib236","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10585-015-9736-z","article-title":"Suppression of lung metastases by the CD26\/DPP4 inhibitor Vildagliptin in mice","volume":"32","author":"Jang","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib238","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.1016\/j.jtho.2016.11.404","article-title":"MA04. 10 lung cancer growth is suppressed by CD26\/DPP4-inhibition via enhanced NK cell and macrophage recruitment","volume":"12","author":"Jang","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib239","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/carcin\/bgz009","article-title":"The CD26\/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity","volume":"40","author":"Jang","year":"2019","journal-title":"Carcinogenesis"},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib237","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10585-015-9736-z","article-title":"Suppression of lung metastases by the CD26\/DPP4 inhibitor Vildagliptin in mice","volume":"32","author":"Jang","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib240","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3892\/ol.2022.13521","article-title":"Dapagliflozin induces apoptosis by downregulating cFILPL and increasing cFILPS instability in Caki-1 cells","volume":"24","author":"Jang","year":"2022","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib241","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3892\/ol.2022.13521","article-title":"Dapagliflozin induces apoptosis by downregulating cFILP(L) and increasing cFILP(S) instability in Caki-1 cells","volume":"24","author":"Jang","year":"2022","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib242","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/jcrt.JCRT_862_16","article-title":"Oxidative stress and its role in cancer","volume":"17","author":"Jelic","year":"2021","journal-title":"J. Cancer Res. Therapeut."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib243","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/dmrr.2810","article-title":"Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program","volume":"32","author":"Jendle","year":"2016","journal-title":"Diabetes Metabol. Res. Rev."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib244","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22220","article-title":"Effect of sitagliptin, a DPP-4 inhibitor, against DENA-induced liver cancer in rats mediated via NF-\u03baB activation and inflammatory cytokines","volume":"32","author":"Jiang","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib245","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22220","article-title":"Effect of sitagliptin, a DPP\u20104 inhibitor, against DENA\u2010induced liver cancer in rats mediated via NF\u2010\u03baB activation and inflammatory cytokines","volume":"32","author":"Jiang","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.mam.2026.101521_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108712","article-title":"Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression","volume":"113","author":"Jiang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mam.2026.101521_bib247","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/1094274","article-title":"Metformin as a potential in vitro anticancer modulator of adenosine monophosphate kinase: a review","volume":"2024","author":"Jinadasa","year":"2024","journal-title":"Int. J. Breast Cancer"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib248","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14636","article-title":"A guideline for the outpatient management of glycaemic control in people with cancer","volume":"39","author":"Joharatnam-Hogan","year":"2022","journal-title":"Diabet. Med. : J. Br. Diabet. Assoc."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib249","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00125-012-2525-1","article-title":"Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence","volume":"55","author":"Johnson","year":"2012","journal-title":"Diabetologia"},{"issue":"20","key":"10.1016\/j.mam.2026.101521_bib250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205237","article-title":"The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: Association with SGLT2 expression in hepatocellular carcinoma","volume":"20","author":"Jojima","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.mam.2026.101521_bib251","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.3390\/ijms20205237","article-title":"The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma","volume":"20","author":"Jojima","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib253","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib252","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00535-013-0783-4","article-title":"Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats","volume":"49","author":"Kaji","year":"2014","journal-title":"J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib254","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijem.IJEM_556_17","article-title":"Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus\u2013International Task Force","volume":"22","author":"Kalra","year":"2018","journal-title":"Indian J. Endocrinol. Metabol."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib255","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s13300-019-0651-1","article-title":"Glucocrinology of modern sulfonylureas: clinical evidence and practice-based opinion from an international expert group","volume":"10","author":"Kalra","year":"2019","journal-title":"Diabetes Ther."},{"issue":"22","key":"10.1016\/j.mam.2026.101521_bib256","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1038\/s41388-021-01822-5","article-title":"Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma","volume":"40","author":"Kamada","year":"2021","journal-title":"Oncogene"},{"issue":"28","key":"10.1016\/j.mam.2026.101521_bib257","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038870","article-title":"Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: a systematic review and meta-analysis","volume":"103","author":"Kamrul-Hasan","year":"2024","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib258","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13046-021-02077-4","article-title":"Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma","volume":"40","author":"Kang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib259","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtho.2020.08.021","article-title":"The associations of aspirin, statins, and metformin with lung cancer risk and related mortality: a time-dependent analysis of population-based nationally representative data","volume":"16","author":"Kang","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib260","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1186\/s12885-025-14304-8","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Karimi","year":"2025","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib261","first-page":"2797","article-title":"Suppressive effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice","volume":"42","author":"Kato","year":"2019","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib262","first-page":"2797","article-title":"Suppressive effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice","volume":"42","author":"Kato","year":"2019","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib263","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3390\/cancers13092191","article-title":"CD26\/DPP-4: type 2 diabetes drug target with potential influence on cancer biology","volume":"13","author":"Kawakita","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib264","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","article-title":"Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis\u2013associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects","volume":"10","author":"Kawakubo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2026.101521_bib265","doi-asserted-by":"crossref","DOI":"10.22317\/jcms.v10i3.1555","article-title":"Synergistic antitumor and apoptotic activity of sitagliptin or linagliptin plus cisplatin against A549 lung cancer cells (an Invitro Study)","volume":"10","author":"Khafaji","year":"2024","journal-title":"J. Contemp. Med. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib266","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115246","article-title":"Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1\/2, p38\u03b1, and NF-\u03baB signaling","volume":"407","author":"Khalil","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib267","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/17425255.2024.2402478","article-title":"Clinical pharmacokinetics of glipizide: a systematic review","volume":"21","author":"Khan","year":"2025","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"issue":"22","key":"10.1016\/j.mam.2026.101521_bib268","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1016\/j.bmcl.2014.09.044","article-title":"Novel benzenesulfonylureas containing thiophenylpyrazoline moiety as potential antidiabetic and anticancer agents","volume":"24","author":"Kharbanda","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib273","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3803\/EnM.2022.1613","article-title":"Metformin and cervical cancer risk in patients with newly diagnosed type 2 diabetes: a population-based study in Korea","volume":"37","author":"Kim","year":"2022","journal-title":"Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib271","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40618-017-0792-x","article-title":"Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells","volume":"41","author":"Kim","year":"2018","journal-title":"J. Endocrinol. Investig."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib269","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4093\/dmj.2016.40.5.339","article-title":"Gemigliptin: an update of its clinical use in the management of type 2 diabetes mellitus","volume":"40","author":"Kim","year":"2016","journal-title":"Diabetes Metabol. J."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib270","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317722068","article-title":"The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells","volume":"39","author":"Kim","year":"2017","journal-title":"Tumor Biol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib272","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12020-017-1503-2","article-title":"Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells","volume":"59","author":"Kim","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib274","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10637-021-01158-7","article-title":"Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer","volume":"40","author":"Kiran","year":"2022","journal-title":"Invest. N. Drugs"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10637-021-01158-7","article-title":"Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer","volume":"40","author":"Kiran","year":"2022","journal-title":"Invest. N. Drugs"},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib276","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1210\/en.2011-1201","article-title":"Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells","volume":"152","author":"Koehler","year":"2011","journal-title":"Endocrinology"},{"issue":"16","key":"10.1016\/j.mam.2026.101521_bib277","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.3390\/ijms21165722","article-title":"Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis","volume":"21","author":"Kojima","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib278","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1507\/endocrj.EJ19-0428","article-title":"SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation","volume":"67","author":"Komatsu","year":"2020","journal-title":"Endocr. J."},{"key":"10.1016\/j.mam.2026.101521_bib279","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2024.10.004","article-title":"Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer","volume":"191","author":"Kong","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib280","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2024.10.004","article-title":"Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer","volume":"191","author":"Kong","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"23","key":"10.1016\/j.mam.2026.101521_bib281","doi-asserted-by":"crossref","first-page":"8976","DOI":"10.3390\/ijms21238976","article-title":"Sitagliptin modulates the response of ovarian cancer cells to chemotherapeutic agents","volume":"21","author":"Kosowska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib282","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.12659\/MSM.902530","article-title":"Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma","volume":"23","author":"Kuang","year":"2017","journal-title":"Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.mam.2026.101521_bib283","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.12659\/MSM.902530","article-title":"Therapeutic effect of sodium glucose Co-Transporter 2 inhibitor dapagliflozin on renal cell carcinoma","volume":"23","author":"Kuang","year":"2017","journal-title":"Med. Sci. Monit."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib284","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.27706","article-title":"Metformin intake is associated with better survival in ovarian cancer: a case\u2010control study","volume":"119","author":"Kumar","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.mam.2026.101521_bib285","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ebiom.2017.10.009","article-title":"Attenuation of CD4+ CD25+ regulatory T cells in the tumor microenvironment by metformin, a type 2 diabetes drug","volume":"25","author":"Kunisada","year":"2017","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib286","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/00003495-199855040-00007","article-title":"Glimepiride: a review of its use in the management of type 2 diabetes mellitus","volume":"55","author":"Langtry","year":"1998","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib287","doi-asserted-by":"crossref","DOI":"10.1177\/0036850419886448","article-title":"Rosiglitazone enhances the apoptotic effect of 5-fluorouracil in colorectal cancer cells with high-glucose-induced glutathione","volume":"103","author":"Lau","year":"2020","journal-title":"Sci. Prog."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib288","doi-asserted-by":"crossref","DOI":"10.1177\/0036850419886448","article-title":"Rosiglitazone enhances the apoptotic effect of 5-fluorouracil in colorectal cancer cells with high-glucose-induced glutathione","volume":"103","author":"Lau","year":"2020","journal-title":"Sci. Prog."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib289","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cen.12667","article-title":"Obesity, adipokines and cancer: an update","volume":"83","author":"Lee","year":"2015","journal-title":"Clin. Endocrinol."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib290","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1210\/jc.2017-00346","article-title":"Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma","volume":"102","author":"Lee","year":"2017","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib292","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00384-020-03765-x","article-title":"Metformin usage and the risk of colorectal cancer: a national cohort study","volume":"36","author":"Lee","year":"2021","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.mam.2026.101521_bib291","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vph.2018.01.001","article-title":"Gliclazide, a KATP channel blocker, inhibits vascular smooth muscle cell proliferation through the CaMKK\u03b2\u2013AMPK pathway","volume":"102","author":"Lee","year":"2018","journal-title":"Vasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib293","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/dom.12582","article-title":"Frequency of cancer events with saxagliptin in the SAVOR\u2010TIMI 53 trial. Diabetes","volume":"18","author":"Leiter","year":"2016","journal-title":"Obes. Metabol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib294","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1038\/s41467-022-35481-1","article-title":"Pharmacological inhibition of Lin28 promotes ketogenesis and restores lipid homeostasis in models of non-alcoholic fatty liver disease","volume":"13","author":"Lekka","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib295","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/cancers17010078","article-title":"Differential effects of GLP-1 receptor agonists on cancer risk in obesity: a nationwide analysis of 1.1 million patients","volume":"17","author":"Levy","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib298","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2026.101521_bib301","article-title":"Transcriptome analysis of liver cancer cell Huh-7 treated with metformin","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mam.2026.101521_bib304","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175592","article-title":"Metformin enhances T lymphocyte anti-tumor immunity by increasing the infiltration via vessel normalization","volume":"944","author":"Li","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib306","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s40001-025-02749-3","article-title":"Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology\u2014a narrative review","volume":"30","author":"Li","year":"2025","journal-title":"Eur. J. Med. Res."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib302","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3892\/etm.2022.11211","article-title":"Anagliptin promotes apoptosis in mouse colon carcinoma cells via MCT-4\/lactate-mediated intracellular acidosis","volume":"23","author":"Li","year":"2022","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib303","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3892\/etm.2022.11211","article-title":"Anagliptin promotes apoptosis in mouse colon carcinoma cells via MCT-4\/lactate-mediated intracellular acidosis","volume":"23","author":"Li","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.mam.2026.101521_bib300","article-title":"Antidiabetic DPP-4 inhibitors reprogram tumor microenvironment that facilitates murine breast cancer metastasis through interaction with cancer cells via a ROS\u2013NF-\u043aB\u2013NLRP3 axis","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib305","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10620-023-08211-w","article-title":"Gliclazide reduces colitis-associated colorectal cancer formation by deceasing colonic inflammation and regulating AMPK-NF-\u03baB signaling pathway","volume":"69","author":"Li","year":"2024","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib296","first-page":"91","article-title":"Glucagon-like peptide-1 analogues inhibit proliferation and increase apoptosis of human prostate cancer cells in vitro","volume":"125","author":"Li","year":"2017","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib297","first-page":"91","article-title":"Glucagon-like Peptide-1 analogues inhibit proliferation and increase apoptosis of human prostate cancer cells in vitro","volume":"125","author":"Li","year":"2017","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.mam.2026.101521_bib299","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fphar.2020.00187","article-title":"Repositioning of hypoglycemic drug linagliptin for cancer treatment","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib307","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12967-025-06122-0","article-title":"Exploring TNFR1: from discovery to targeted therapy development","volume":"23","author":"Li","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mam.2026.101521_bib308","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.894285","article-title":"Methyl gallate suppresses the migration, invasion, and epithelial-mesenchymal transition of hepatocellular carcinoma cells via the AMPK\/NF-\u03baB signaling pathway in vitro and in vivo","volume":"13","author":"Liang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib309","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.celrep.2017.04.004","article-title":"Sirtuin-1 activation controls tumor growth by impeding Th17 differentiation via STAT3 deacetylation","volume":"19","author":"Limagne","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomarker Res."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib312","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-026-01788-5","article-title":"Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants","volume":"19","author":"Lin","year":"2026","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib311","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/jtd-24-1152","article-title":"Causal relationship between type II diabetes mellitus, metformin, insulin, gliclazide, and esophageal cancer\u2014insights from two-sample Mendelian randomization study and meta-analysis","volume":"17","author":"Lin","year":"2025","journal-title":"J. Thorac. Dis."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib313","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.2337\/dc20-0204","article-title":"Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people","volume":"43","author":"Ling","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib314","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0257","article-title":"Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?","volume":"12","author":"Lisco","year":"2023","journal-title":"Endocrine Connect."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib322","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad139","article-title":"Research progress of metformin in the treatment of oral squamous cell carcinoma","volume":"164","author":"Liu","year":"2023","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1091581809335312","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonist rosiglitazone\u2013induced apoptosis in leukemia K562 cells and its mechanisms of action","volume":"28","author":"Liu","year":"2009","journal-title":"Int. J. Toxicol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib316","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1091581809335312","article-title":"Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone--induced apoptosis in leukemia k562 cells and its mechanisms of action","volume":"28","author":"Liu","year":"2009","journal-title":"Int. J. Toxicol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib320","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/cancers14030486","article-title":"High metabolic dependence on oxidative phosphorylation drives sensitivity to metformin treatment in MLL\/AF9 acute myeloid leukemia","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2026.101521_bib319","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.586760","article-title":"Pleiotropic effects of metformin on the antitumor efficiency of immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib323","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1021\/acs.jproteome.3c00498","article-title":"Effect of semaglutide on high-fat-diet-induced liver cancer in obese mice","volume":"23","author":"Liu","year":"2024","journal-title":"J. Proteome Res."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib317","first-page":"4253","article-title":"Real-time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib318","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12935-019-0732-2","article-title":"Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK\/p21 pathway","volume":"19","author":"Liu","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mam.2026.101521_bib321","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120370","article-title":"Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4\/ROS\/VEGF pathway","volume":"294","author":"Liu","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.mam.2026.101521_bib324","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.2147\/OTT.S240252","article-title":"The anti-breast cancer effect and mechanism of glimepiride-metformin adduct","author":"Long","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.mam.2026.101521_bib325","series-title":"The Anti-breast Cancer Effect and Mechanism of glimepiride-metformin Adduct","first-page":"3777","author":"Long","year":"2020"},{"key":"10.1016\/j.mam.2026.101521_bib326","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176328","article-title":"Investigation of co-treatment multi-targeting approaches in breast cancer cell lines","volume":"966","author":"Longaray","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mam.2026.101521_bib327","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176328","article-title":"Investigation of co-treatment multi-targeting approaches in breast cancer cell lines","volume":"966","author":"Longaray","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib328","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cmet.2018.08.021","article-title":"Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer","volume":"28","author":"Lord","year":"2018","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib330","first-page":"1271","article-title":"Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR\/AKT signaling","volume":"54","author":"Lu","year":"2019","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib329","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198938","article-title":"Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells","volume":"13","author":"Lu","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib331","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100872","article-title":"Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6\/STAT3 signaling in hepatocellular carcinoma","volume":"14","author":"Lu","year":"2021","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib332","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100872","article-title":"Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6\/STAT3 signaling in hepatocellular carcinoma","volume":"14","author":"Lu","year":"2021","journal-title":"Transl. Oncol."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib334","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.trecan.2025.04.010","article-title":"Repurposing glucose-lowering drugs for cancer therapy","volume":"11","author":"Luconi","year":"2025","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib333","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/ERC-09-0170","article-title":"Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model","volume":"17","author":"Luconi","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"issue":"23","key":"10.1016\/j.mam.2026.101521_bib335","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.1039\/D5FO03273C","article-title":"GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies","volume":"16","author":"Luo","year":"2025","journal-title":"Food Funct."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib336","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00210-016-1291-x","article-title":"Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor \u03b3-independent mechanism","volume":"390","author":"L\u00fctzen","year":"2017","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib337","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00210-016-1291-x","article-title":"Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor \u03b3-independent mechanism","volume":"390","author":"L\u00fctzen","year":"2017","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib338","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/carcin\/bgp260","article-title":"Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model","volume":"30","author":"Lyon","year":"2009","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib339","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12885-023-11077-w","article-title":"High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib340","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.neo.2019.03.007","article-title":"Metformin regulates the expression of CD133 through the AMPK-CEBP\u03b2 pathway in hepatocellular carcinoma cell lines","volume":"21","author":"Maehara","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.mam.2026.101521_bib341","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.fct.2012.09.006","article-title":"Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines","volume":"51","author":"Mahmoud","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.mam.2026.101521_bib342","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.fct.2012.09.006","article-title":"Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines","volume":"51","author":"Mahmoud","year":"2013","journal-title":"Food Chem. Toxicol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib343","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.70206","article-title":"Linagliptin mitigates DMH\u2010Induced colorectal cancer in rats: crosstalk between NFAT and IL\u20106\/JAK2\/STAT3\/NF\u2010\u03baB signaling hubs","volume":"39","author":"Mahmoud","year":"2025","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib344","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00126839-200607060-00002","article-title":"Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data","volume":"7","author":"Malaisse","year":"2006","journal-title":"Drugs R&D"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib345","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jcpt.13259","article-title":"Glucagon\u2010like peptide\u20101 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database","volume":"46","author":"Mali","year":"2021","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib346","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/stem.1376","article-title":"NPRA signaling regulates stem cell recruitment and angiogenesis: a model to study linkage between inflammation and tumorigenesis","volume":"31","author":"Mallela","year":"2013","journal-title":"Stem cells (Dayton, Ohio)"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib347","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3892\/ijo.2010.877","article-title":"Thiazolidinediones\/PPAR\u03b3 agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer","volume":"38","author":"Mansour","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib348","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2174\/1871520621666210910085733","article-title":"Glipizide combined with ANP suppresses breast cancer growth and metastasis by inhibiting angiogenesis through VEGF\/VEGFR2 signaling","volume":"22","author":"Mao","year":"2022","journal-title":"Anti-Cancer Agents Med. Chem.-Anti-Cancer Agents)"},{"key":"10.1016\/j.mam.2026.101521_bib349","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1115543","article-title":"Immunohistochemical, pharmacovigilance, and omics analyses reveal the involvement of ATP-sensitive K+ channel subunits in cancers: role in drug\u2013disease interactions","volume":"14","author":"Maqoud","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib350","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s44324-025-00054-5","article-title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","volume":"3","author":"Marathe","year":"2025","journal-title":"Npj Metabol. Health Dis."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib351","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s44324-025-00054-5","article-title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","volume":"3","author":"Marathe","year":"2025","journal-title":"NPJ. Metab. Health Dis."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib352","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1073\/pnas.120069197","article-title":"Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26","volume":"97","author":"Marguet","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib353","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1210\/jc.2004-2460","article-title":"Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed \u03b2-cell function in patients with type 2 diabetes","volume":"90","author":"Mari","year":"2005","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib354","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2337\/diab.33.5.495","article-title":"Tolbutamide stimulates fructose-2, 6-bisphosphate formation in perfused rat liver","volume":"33","author":"Matsutani","year":"1984","journal-title":"Diabetes"},{"key":"10.1016\/j.mam.2026.101521_bib355","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/9781681082493116090005","article-title":"Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme","volume":"9","author":"Matteucci","year":"2016","journal-title":"Front. Med. Chem."},{"key":"10.1016\/j.mam.2026.101521_bib356","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/OPTH.S287747","article-title":"Serum malondialdehyde as a biomarker of oxidative stress in patients with primary ocular carcinoma: impact on response to chemotherapy","volume":"15","author":"Maurya","year":"2021","journal-title":"Clin. Ophthalmol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib357","doi-asserted-by":"crossref","first-page":"H1139","DOI":"10.1152\/ajpheart.1995.268.3.H1139","article-title":"ANP increases capillary permeability to protein independent of perfusate protein composition","volume":"268","author":"McKay","year":"1995","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib358","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr. Rev."},{"issue":"7515","key":"10.1016\/j.mam.2026.101521_bib359","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0140-6736(67)90502-8","article-title":"Chlorpropamide treatment in diabetes insipidus","volume":"290","author":"Meinders","year":"1967","journal-title":"Lancet"},{"key":"10.1016\/j.mam.2026.101521_bib360","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3389\/fonc.2020.00584","article-title":"Tumor necrosis factor \u03b1 blockade: an opportunity to tackle breast cancer","volume":"10","author":"Mercogliano","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib361","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/DDDT.S485755","article-title":"Research progress of SGLT2 inhibitors in cancer treatment. Drug design","volume":"19","author":"Miao","year":"2025","journal-title":"development therapy"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib362","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1210\/endo-86-5-1024","article-title":"Potentiation of vasopressin action by chlorpropamide in vivo","volume":"86","author":"Miller","year":"1970","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2026.101521_bib363","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20200679","article-title":"Metformin inhibits the growth of ovarian cancer cells by promoting the Parkin-induced p53 ubiquitination","author":"Min","year":"2020","journal-title":"Biosci. Rep."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib364","first-page":"321","article-title":"Phase 2 trial of metformin combined with 5-fluorouracil in patients with refractory metastatic colorectal cancer","volume":"15","author":"Miranda","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib365","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib366","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/a-2237-8566","article-title":"Encyclopaedic review of glipizide pre-clinical and clinical status","volume":"74","author":"Mohammed","year":"2024","journal-title":"Drug Research"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib367","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/ijms26010247","article-title":"Antiproliferative mechanisms of metformin in breast cancer: a systematic review of the literature","volume":"26","author":"Moldasheva","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib368","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2337\/dc07-2308","article-title":"Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials","volume":"31","author":"Monami","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mam.2026.101521_bib369","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2026.01.024","article-title":"Glucocorticoid-induced hyperglycemia in patients with cancer: mechanisms, clinical implications, and management strategies","author":"Morikawa","year":"2026","journal-title":"Endocr. Pract. : Off. Je Am. College Endocrinol. Am. Assoc. Clini"},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib370","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtho.2018.07.102","article-title":"Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS\/LKB1 NSCLC","volume":"13","author":"Moro","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib371","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1189\/jlb.3MR0915-401R","article-title":"CD26\/dipeptidylpeptidase IV\u2014Chemokine interactions: double-edged regulation of inflammation and tumor biology","volume":"99","author":"Mortier","year":"2016","journal-title":"J. Leuc. Biol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib372","doi-asserted-by":"crossref","first-page":"75","DOI":"10.18388\/abp.2008_3203","article-title":"Pioglitazone, a PPAR-gamma ligand, exerts cytostatic\/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome","volume":"55","author":"Mr\u00f3wka","year":"2008","journal-title":"Acta Biochim. Pol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib373","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib374","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/bcp.13021","article-title":"AKT in cancer: new molecular insights and advances in drug development","volume":"82","author":"Mundi","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib375","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3346\/jkms.2017.32.9.1385","article-title":"Sirolimus and metformin synergistically inhibits colon cancer in vitro and in vivo","volume":"32","author":"Mussin","year":"2017","journal-title":"J. Kor. Med. Sci."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib376","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib377","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib378","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-018-0806-0","article-title":"Insulin\/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer","volume":"17","author":"Mutgan","year":"2018","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib379","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metabol. Syndr.: Clin. Res. Rev."},{"key":"10.1016\/j.mam.2026.101521_bib380","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112864","article-title":"Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans","volume":"149","author":"Nakachi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mam.2026.101521_bib381","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112864","article-title":"Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans","volume":"149","author":"Nakachi","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib382","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232283","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","author":"Nakano","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib383","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084369","article-title":"Metformin: a potential therapeutic agent for recurrent colon cancer","volume":"9","author":"Nangia-Makker","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib384","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metabol."},{"key":"10.1016\/j.mam.2026.101521_bib385","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118870","article-title":"Vildagliptin, a dipeptidyl peptidase-4 inhibitor, reduces betel-nut induced carcinogenesis in female mice","volume":"266","author":"Nath","year":"2021","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib386","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc17-1825","article-title":"Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial","volume":"41","author":"Nauck","year":"2018","journal-title":"Diabetes Care"},{"issue":"59","key":"10.1016\/j.mam.2026.101521_bib387","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.21754","article-title":"Glipizide sensitizes lung cancer cells to TRAIL-induced apoptosis via Akt\/mTOR\/autophagy pathways","volume":"8","author":"Nazim","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib388","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/13880209.2024.2374794","article-title":"Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy","volume":"62","author":"Ni","year":"2024","journal-title":"Pharm. Biol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib389","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/cancers14020454","article-title":"CD26\/DPP4 as a therapeutic target in nonalcoholic steatohepatitis associated hepatocellular carcinoma","volume":"14","author":"Nishina","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib390","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","article-title":"Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice","volume":"7","author":"Nishina","year":"2019","journal-title":"Cellular Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib391","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","article-title":"Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice","volume":"7","author":"Nishina","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib392","first-page":"357","article-title":"GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control","volume":"11","author":"Nomiyama","year":"2016","journal-title":"Expert Rev. Endocrinol. Metabol."},{"key":"10.1016\/j.mam.2026.101521_bib393","article-title":"Metabolic modulation of CD8+ T cells by metformin: a promising adjuvant strategy for CD8+ T cell-based immunotherapies","author":"Nu","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mam.2026.101521_bib394","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2050-6511-14-6","article-title":"Glibenclamide inhibits cell growth by inducing G0\/G1 arrest in the human breast cancer cell line MDA-MB-231","volume":"14","author":"N\u00fa\u00f1ez","year":"2013","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib402","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jnci\/djae021","article-title":"Association of metformin use and cancer incidence: a systematic review and meta-analysis","volume":"116","author":"O\u2019connor","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mam.2026.101521_bib403","article-title":"Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis","volume":"14","author":"O'Reilly","year":"2024","journal-title":"Front. Oncol."},{"issue":"35","key":"10.1016\/j.mam.2026.101521_bib395","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16874","article-title":"Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice","volume":"8","author":"Obara","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib396","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25030495","article-title":"Dapagliflozin inhibits cell adhesion to collagen I and IV and increases ectodomain proteolytic cleavage of DDR1 by increasing ADAM10 activity","volume":"25","author":"Okada","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib397","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/10245332.2016.1265780","article-title":"Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia","volume":"22","author":"Olarte Carrillo","year":"2017","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib398","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/ijms23010430","article-title":"The YAP\/TAZ signaling pathway in the tumor microenvironment and carcinogenesis: current knowledge and therapeutic promises","volume":"23","author":"Ortega","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib399","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-201x.2001.00826.x","article-title":"The pathophysiology of type 2 diabetes mellitus: an overview","volume":"171","author":"\u00d6stenson","year":"2001","journal-title":"Acta Physiol. Scand."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib400","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22547","article-title":"Effects of metformin and pioglitazone combination on apoptosis and AMPK\/mTOR signaling pathway in human anaplastic thyroid cancer cells","volume":"34","author":"Ozdemir Kutbay","year":"2020","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib401","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22547","article-title":"Effects of metformin and pioglitazone combination on apoptosis and AMPK\/mTOR signaling pathway in human anaplastic thyroid cancer cells","volume":"34","author":"Ozdemir Kutbay","year":"2020","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.mam.2026.101521_bib404","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.biochi.2025.03.002","article-title":"Metformin's anticancer odyssey: revealing multifaceted mechanisms across diverse neoplastic terrains- a critical review","volume":"233","author":"Pal","year":"2025","journal-title":"Biochimie"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib405","doi-asserted-by":"crossref","first-page":"812","DOI":"10.37349\/etat.2023.00170","article-title":"AGEs and RAGE: metabolic and molecular signatures of the glycation-inflammation axis in malignant or metastatic cancers","volume":"4","author":"Palanissami","year":"2023","journal-title":"Explor Target Antitumor Ther."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib406","first-page":"7092","article-title":"Formulation and characterization of nanostructured lipid carriers of tolbutamide for the treatment of type II diabetes","volume":"6","author":"Pandey","year":"2024","journal-title":"CAHIERS MAGELLANES-NS"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib407","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/1574886317666220304124756","article-title":"Pioglitazone, bladder cancer, and the presumption of innocence","volume":"17","author":"Papaetis","year":"2022","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.mam.2026.101521_bib408","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","article-title":"Metabolic adaptation in hypoxia and cancer","volume":"502","author":"Paredes","year":"2021","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib409","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3343\/alm.2023.0443","article-title":"Metformin suppresses both PD-L1 expression in cancer cells and cancer-induced PD-1 expression in immune cells to promote antitumor immunity","volume":"44","author":"Park","year":"2024","journal-title":"Annals Labor. Med."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib410","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1634\/theoncologist.2013-0177","article-title":"Effects of sulfonylureas on tumor growth: a review of the literature","volume":"18","author":"Pasello","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib411","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-74277-9","article-title":"Combination of paclitaxel with rosiglitazone induces synergistic cytotoxic effects in ovarian cancer cells","volume":"14","author":"Patel","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib412","first-page":"686","article-title":"Influence of harvesting time on the chemical composition of wild stinging nettle","volume":"10","author":"Paulauskien\u0117","year":"2021","journal-title":"Urtica dioica L.)"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib413","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib414","first-page":"846","article-title":"Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia","volume":"146","author":"Pe\u00f1afiel","year":"2018","journal-title":"Rev. Med. Chile"},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib415","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102640","article-title":"Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Permana","year":"2022","journal-title":"Diabetes Metabol. Syndr.: Clin. Res. Rev."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib416","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2014Mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib417","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41574-021-00489-y","article-title":"Novel therapies with precision mechanisms for type 2 diabetes mellitus","volume":"17","author":"Perreault","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib419","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1210\/jcem-53-6-1256","article-title":"Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus","volume":"53","author":"Pfeifer","year":"1981","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib420","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib421","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41467-024-47359-5","article-title":"Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk","volume":"15","author":"Piening","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib422","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41467-024-47359-5","article-title":"Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk","volume":"15","author":"Piening","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib423","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.32439","article-title":"Diabetes medications and risk of HCC","volume":"76","author":"Plaz Torres","year":"2022","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib424","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","article-title":"Canagliflozin: a review of its use in patients with type 2 diabetes mellitus","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib425","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mam.2026.101521_bib426","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111758","article-title":"Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"213","author":"Popovic","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.mam.2026.101521_bib427","article-title":"Evaluation of the effect of metformin as a radiosensitiser in solid tumours: a systematic review","volume":"52","author":"Portillo","year":"2025","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"suppl_3","key":"10.1016\/j.mam.2026.101521_bib428","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.S368","article-title":"Sulfonylurea stimulation of insulin secretion","volume":"51","author":"Proks","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.mam.2026.101521_bib429","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.685923","article-title":"Targeting adipokines in obesity-related tumors","volume":"11","author":"Pu","year":"2021","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib430","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31083\/j.fbl2810259","article-title":"The effect of liraglutide on lung cancer and its potential protective effect on high glucose-induced lung senescence and oxidative damage","volume":"28","author":"Pu","year":"2023","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib431","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31083\/j.fbl2810259","article-title":"The effect of liraglutide on lung cancer and its potential protective effect on high glucose-induced lung senescence and oxidative damage","volume":"28","author":"Pu","year":"2023","journal-title":"Frontiers in Biosci.-Landmark"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib433","doi-asserted-by":"crossref","DOI":"10.1038\/srep27819","article-title":"Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis","volume":"6","author":"Qi","year":"2016","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.mam.2026.101521_bib432","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.18632\/oncotarget.2483","article-title":"Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis","volume":"5","author":"Qi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.mam.2026.101521_bib436","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2018.01.064","article-title":"Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2","volume":"420","author":"Qin","year":"2018","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib434","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3892\/mmr.2014.2232","article-title":"Peroxisome proliferator-activated receptor \u03b3 agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4\/CXCL12 axis","volume":"10","author":"Qin","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib435","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3892\/mmr.2014.2232","article-title":"Peroxisome proliferator-activated receptor \u03b3 agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4\/CXCL12 axis","volume":"10","author":"Qin","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib437","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/7133198","article-title":"Synergistic inhibitory effect of gliquidone against cisplatin\u2010resistant human lung adenocarcinoma","volume":"2024","author":"Qiu","year":"2024","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"Supplement_2","key":"10.1016\/j.mam.2026.101521_bib438","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.3253","article-title":"SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, leukotrienes\/interleukin 6 axis and mTORC1\/Fox01\/3a mediated apoptosis","volume":"41","author":"Quagliariello","year":"2020","journal-title":"Eur. Heart J."},{"issue":"suppl_3","key":"10.1016\/j.mam.2026.101521_bib439","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.2337\/diabetes.53.suppl_3.S156","article-title":"The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium","volume":"53","author":"Quast","year":"2004","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib440","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4161\/cc.4.4.1583","article-title":"The PPAR-? Agonist Pioglitazone post-trancriptionally induces p21 in PC3 prostate cancer but not in other cell lines","volume":"4","author":"Radhakrishnan","year":"2005","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib441","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1213\/ANE.0000000000006791","article-title":"Society for ambulatory anesthesia updated consensus statement on perioperative blood glucose management in adult patients with diabetes mellitus undergoing ambulatory surgery","volume":"139","author":"Rajan","year":"2024","journal-title":"Anesth. Analg."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib442","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12967-018-1620-6","article-title":"Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene","volume":"16","author":"Ramos-Pe\u00f1afiel","year":"2018","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib443","article-title":"Metformin: a dual-role player in cancer treatment and prevention: a comprehensive systematic review and meta-analysis","volume":"61","author":"Rangraze","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib444","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/medicina61061021","article-title":"Metformin: a dual-role player in cancer treatment and prevention: a comprehensive systematic review and meta-analysis","volume":"61","author":"Rangraze","year":"2025","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib445","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.109.899377","article-title":"DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease","volume":"3","author":"Read","year":"2010","journal-title":"Circ., Cardiovasc. Imaging"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib446","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1530\/eje.0.1460717","article-title":"Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice","volume":"146","author":"Reimer","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mam.2026.101521_bib447","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.canlet.2021.07.035","article-title":"SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis","volume":"519","author":"Ren","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mam.2026.101521_bib448","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2024.07.008","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: a review for the gynecologic oncologist","volume":"190","author":"Riedinger","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib449","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.yexcr.2007.10.005","article-title":"TNF\u03b1 acting on TNFR1 promotes breast cancer growth via p42\/P44 MAPK, JNK, Akt and NF-\u03baB-dependent pathways","volume":"314","author":"Rivas","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.mam.2026.101521_bib450","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154843","article-title":"Incretin-based therapies in 2021\u2013Current status and perspectives for the future","volume":"122","author":"Rizzo","year":"2021","journal-title":"Metabolism"},{"issue":"17","key":"10.1016\/j.mam.2026.101521_bib451","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib452","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1358\/dot.2014.50.11.2232267","article-title":"Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes","volume":"50","author":"Rosenwasser","year":"2014","journal-title":"Drugs Today"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib453","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0192623312472402","article-title":"On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice","volume":"41","author":"Rosol","year":"2013","journal-title":"Toxicol. Pathol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib454","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/MMBR.68.2.320-344.2004","article-title":"ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions","volume":"68","author":"Roux","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib455","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance","volume":"13","author":"Rozengurt","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.mam.2026.101521_bib456","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115817","article-title":"Metformin exhibits antineoplastic effects on Pten-deficient endometrial cancer by interfering with TGF-\u03b2 and p38\/ERK MAPK signalling","volume":"168","author":"Ruiz-Mitjana","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib457","article-title":"Evolution of tolbutamide in the treatment of diabetes mellitus","volume":"2","author":"Saha","year":"2020","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib458","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s13300-024-01612-8","article-title":"Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review","volume":"15","author":"Sahin","year":"2024","journal-title":"Diabetes Ther."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib459","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.31557\/APJCP.2024.25.9.3293","article-title":"Antiproliferative impact of linagliptin on the cervical cancer cell line","volume":"25","author":"Said","year":"2024","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.mam.2026.101521_bib460","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106383","article-title":"Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase","volume":"94","author":"Saito","year":"2020","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib461","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2012.10.032","article-title":"Direct actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulation","volume":"58","author":"Samson","year":"2013","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib462","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: clinical use in type 2 diabetes","volume":"60","author":"Sanchez-Rangel","year":"2017","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib463","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/glia.20363","article-title":"Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up\u2010regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation","volume":"54","author":"S\u00e1nchez\u2010Alvarez","year":"2006","journal-title":"Glia"},{"issue":"467","key":"10.1016\/j.mam.2026.101521_bib464","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5933","article-title":"Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma","volume":"10","author":"Scafoglio","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib465","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3390\/biom10121617","article-title":"Isoform-and paralog-switching in IR-signaling: when diabetes opens the gates to cancer","volume":"10","author":"Scalia","year":"2020","journal-title":"Biomolecules"},{"issue":"34","key":"10.1016\/j.mam.2026.101521_bib466","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41388-023-02772-w","article-title":"Exploitation of ATP-sensitive potassium ion (KATP) channels by HPV promotes cervical cancer cell proliferation by contributing to MAPK\/AP-1 signalling","volume":"42","author":"Scarth","year":"2023","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.mam.2026.101521_bib467","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1042\/BCJ20210377","article-title":"PEPT1 is essential for the growth of pancreatic cancer cells: a viable drug target","volume":"478","author":"Schniers","year":"2021","journal-title":"Biochem. J."},{"issue":"14","key":"10.1016\/j.mam.2026.101521_bib468","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib469","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/leu.2013.107","article-title":"Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells","volume":"27","author":"Scotland","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib470","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40265-020-01260-9","article-title":"Dulaglutide: a review in type 2 diabetes","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib471","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4239\/wjd.v15.i6.1178","article-title":"Metformin-associated lactic acidosis: a mini review of pathophysiology, diagnosis and management in critically ill patients","volume":"15","author":"See","year":"2024","journal-title":"World J. Diabetes"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib472","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3892\/mco.2024.2756","article-title":"Current findings on the antitumor effects of metformin on esophageal squamous cell carcinoma","volume":"21","author":"Sekino","year":"2024","journal-title":"Mol. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib473","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ijc.31783","article-title":"Use of metformin and survival of patients with high\u2010grade glioma","volume":"144","author":"Seliger","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib474","first-page":"97","article-title":"Studies on the phototoxic effects of oral antidiabetics and diuretics","volume":"47","author":"Selvaag","year":"1997","journal-title":"Arzneimittel-forschung"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib475","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40264-023-01305-4","article-title":"The effect of metformin on chemotherapy-induced toxicities in non-diabetic breast cancer patients: a randomised controlled study","volume":"46","author":"Serageldin","year":"2023","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib476","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/a-1345-7890","article-title":"Growth promotion and increased ATP-binding cassette transporters expression by liraglutide in triple negative breast cancer cell line MDA-MB-231","volume":"71","author":"Shadboorestan","year":"2021","journal-title":"Drug Research"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib477","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/a-1345-7890","article-title":"Growth promotion and increased ATP-binding cassette transporters expression by liraglutide in triple negative breast cancer cell line MDA-MB-231","volume":"71","author":"Shadboorestan","year":"2021","journal-title":"Drug Res."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib478","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115694","article-title":"Advances in anti-cancer drug development: Metformin as anti-angiogenic supplemental treatment for glioblastoma","volume":"25","author":"Shah","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib484","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1080\/07391102.2023.2298734","article-title":"Discovery of non-peptide GLP-1r natural agonists for enhancing coronary safety in type 2 diabetes patients","volume":"43","author":"Shakour","year":"2025","journal-title":"J. Biomol. Struct. Dynam."},{"key":"10.1016\/j.mam.2026.101521_bib485","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocs.2024.102497","article-title":"Novel hits for targeting kidney failure in type 2 diabetes derived via in silico screening of the ZINC natural product database","volume":"85","author":"Shakour","year":"2025","journal-title":"J. Comput. Sci."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib481","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102934","article-title":"Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: a comprehensive review","volume":"18","author":"Shakour","year":"2024","journal-title":"Diabetes Metabol. Syndr.: Clin. Res. Rev."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib482","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108897","article-title":"Antioxidant effects of a novel pioglitazone analogue (PA9) in a rat model of diabetes: modulation of redox homeostasis and preservation of tissue architecture","volume":"38","author":"Shakour","year":"2024","journal-title":"J. Diabetes Complicat."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib483","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s10735-024-10272-8","article-title":"Serum biochemical evaluation following administration of imidazolyl thiazolidinedione in streptozotocin-induced diabetic rats","volume":"55","author":"Shakour","year":"2024","journal-title":"J. Mol. Histol."},{"key":"10.1016\/j.mam.2026.101521_bib479","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105162","article-title":"Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents","volume":"115","author":"Shakour","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib480","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/mdr.2022.0134","article-title":"Evaluating the antivirulence effects of new thiazolidinedione compounds against Pseudomonas aeruginosa PAO1","volume":"28","author":"Shakour","year":"2022","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.mam.2026.101521_bib486","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2024.125714","article-title":"Vibrational spectra of second generation antidiabetic drug gliquidone exhibiting anticancer activity, antioxidant activity using both the experimental and theoretical approach","volume":"411","author":"Shamona","year":"2024","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.mam.2026.101521_bib487","series-title":"Metabolic Syndrome Obesity: Targets Therapy","first-page":"251","article-title":"Teneligliptin in management of type 2 diabetes mellitus","author":"Sharma","year":"2016"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib488","article-title":"Association of pioglitazone with major adverse cardiovascular events, all-cause mortality, and heart failure hospitalizations: a systematic review","volume":"15","author":"Sheikh","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib489","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/dme.13437","article-title":"No calcitonin change in a person taking dulaglutide diagnosed with pre\u2010existing medullary thyroid cancer","volume":"35","author":"Sherman","year":"2018","journal-title":"Diabet. Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib493","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/ijgc-2018-000060","article-title":"Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis","volume":"29","author":"Shi","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib491","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/CAD.0000000000000266","article-title":"The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell","volume":"26","author":"Shi","year":"2015","journal-title":"Anti Cancer Drugs"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib490","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Shi","year":"2012","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib492","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3892\/mmr.2016.5592","article-title":"Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo","volume":"14","author":"Shi","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib494","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/ijms25010609","article-title":"Preclinical repurposing of sitagliptin as a drug candidate for colorectal cancer by targeting CD24\/CTNNB1\/SOX4-centered signaling hub","volume":"25","author":"Shih","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib495","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010609","article-title":"Preclinical repurposing of sitagliptin as a drug candidate for colorectal cancer by targeting CD24\/CTNNB1\/SOX4-Centered signaling hub","volume":"25","author":"Shih","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib496","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101658","article-title":"Anti-diabetic medications and the risk for colorectal cancer: a population-based nested case-control study","volume":"64","author":"Shin","year":"2020","journal-title":"Cancer Epidemiol."},{"issue":"35","key":"10.1016\/j.mam.2026.101521_bib497","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2016.67.4044","article-title":"Type 2 diabetes mellitus and cancer: the role of pharmacotherapy","volume":"34","author":"Shlomai","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib498","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10571-022-01221-8","article-title":"Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK","volume":"43","author":"Shoda","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib499","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10571-022-01221-8","article-title":"Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK","volume":"43","author":"Shoda","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib500","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP\u20101 receptor agonists and the risk for cancer: a meta\u2010analysis of randomized controlled trials. Diabetes","volume":"27","author":"Silverii","year":"2025","journal-title":"Obes. Metabol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib501","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102062","volume":"8","author":"Silvestris","year":"2023","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib502","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.20.4.597","article-title":"Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials","volume":"20","author":"Simonson","year":"1997","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib503","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/bjd\/ljae341","article-title":"Association between prescribed oral antidiabetic medication for type 2 diabetes mellitus and risk of skin cancer: a systematic review and meta-analysis","volume":"192","author":"Simpson","year":"2025","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib504","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41571-021-00539-4","article-title":"Therapeutic targeting of the hypoxic tumour microenvironment","volume":"18","author":"Singleton","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.mam.2026.101521_bib505","doi-asserted-by":"crossref","first-page":"22183","DOI":"10.1021\/am505848p","article-title":"Dextran-gated, multifunctional mesoporous nanoparticle for glucose-responsive and targeted drug delivery","volume":"6","author":"Sinha","year":"2014","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib506","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/03639045.2022.2108829","article-title":"Empagliflozin containing chitosan-alginate nanoparticles in orodispersible film: preparation, characterization, pharmacokinetic evaluation and its in-vitro anticancer activity","volume":"48","author":"Sinha","year":"2022","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib507","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17050558","article-title":"Metformin-based combination approaches for triple-negative breast cancer","volume":"17","author":"Sirhan","year":"2025","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib508","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaoncol.2021.2318","article-title":"Addition of metformin to concurrent chemoradiation in patients with locally advanced non\u2013small cell lung cancer: the NRG-LU001 phase 2 randomized clinical trial","volume":"7","author":"Skinner","year":"2021","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib509","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s00125-023-05972-x","article-title":"Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study","volume":"66","author":"Skriver","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.mam.2026.101521_bib510","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biopha.2017.02.010","article-title":"Combination of sitagliptin and silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats","volume":"89","author":"Sokar","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib511","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1007\/s12094-024-03502-8","article-title":"SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)","volume":"26","author":"Soria Rivas","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib512","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117668","article-title":"Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity","volume":"181","author":"Stanisavljevic","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mam.2026.101521_bib513","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117668","article-title":"Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity","volume":"181","author":"Stanisavljevic","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib514","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0168-8278(97)80180-8","article-title":"Aberrant dipeptidyl peptidase IV (DPP IV\/CD26) expression in human hepatocellular carcinoma","volume":"27","author":"Stecca","year":"1997","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib515","article-title":"The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer","volume":"4","author":"Stein","year":"2024","journal-title":"Endocr. Oncol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib516","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/152091501300209633","article-title":"The relation of type 2 diabetes and cancer","volume":"3","author":"Strickler","year":"2001","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.mam.2026.101521_bib517","article-title":"Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib518","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2024.101585","article-title":"Association of SGLT2 inhibitors with incident cancer","volume":"50","author":"Suzuki","year":"2024","journal-title":"Diabetes Metabol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib519","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/curroncol31020075","article-title":"Insulin resistance: the increased risk of cancers","volume":"31","author":"Szablewski","year":"2024","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib520","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/ph16010115","article-title":"Metformin induces apoptosis in human pancreatic cancer (PC) cells accompanied by changes in the levels of histone acetyltransferases (particularly, p300\/CBP-Associated factor (PCAF) protein levels)","volume":"16","author":"Szymczak-Pajor","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib521","doi-asserted-by":"crossref","DOI":"10.2174\/0115733998349193250207045239","article-title":"Circulating biomarkers as a window into the relationship between sarcopenia and diabetes: implications for effective management","volume":"22","author":"Tajik","year":"2026","journal-title":"Curr. Diabetes Rev."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib522","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-007-9575-y","article-title":"Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells","volume":"108","author":"Talbert","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib523","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-007-9575-y","article-title":"Transactivation of ER\u03b1 by rosiglitazone induces proliferation in breast cancer cells","volume":"108","author":"Talbert","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib524","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13340-021-00560-z","article-title":"Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth","volume":"13","author":"Tanaka","year":"2022","journal-title":"Diabetology Int."},{"issue":"24","key":"10.1016\/j.mam.2026.101521_bib525","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2217\/epi-2023-0332","article-title":"Dulaglutide as a demethylating agent to improve the outcome of breast cancer","volume":"15","author":"Tatsch","year":"2023","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib526","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41598-018-38004-5","article-title":"Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities","volume":"9","author":"Thomale","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib527","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12094-015-1412-x","article-title":"Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis","volume":"18","author":"Tian","year":"2016","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib528","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2407-9-107","article-title":"Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz {a} anthracene (DMBA) induced breast cancer rats","volume":"9","author":"Tikoo","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mam.2026.101521_bib529","series-title":"Encyclopedia of Molecular Pharmacology","first-page":"261","article-title":"ATP-dependent K+ channels","author":"Tinker","year":"2022"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib530","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3390\/ijms26041429","article-title":"Combining sulfonylureas with anticancer drugs: evidence of synergistic efficacy with doxorubicin in vitro and in vivo","volume":"26","author":"Tomczyk","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib531","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3390\/ijms26041429","article-title":"Combining sulfonylureas with anticancer drugs: evidence of synergistic efficacy with doxorubicin in vitro and in vivo","volume":"26","author":"Tomczyk","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2026.101521_bib532","series-title":"Sulfonylureas Beyond Diabetes: a Comprehensive Review on Anticancer and Off-Target Effects (1956-2025)","author":"Tomczyk","year":"2026"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib533","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14656566.2021.1999413","article-title":"The role of sulfonylureas in the treatment of type 2 diabetes","volume":"23","author":"Tomlinson","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.mam.2026.101521_bib534","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mam.2026.101521_bib535","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib536","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64774-2","article-title":"Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo","volume":"14","author":"Trakoonsenathong","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib537","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64774-2","article-title":"Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo","volume":"14","author":"Trakoonsenathong","year":"2024","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib538","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.nut.2013.12.005","article-title":"Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia","volume":"30","author":"Trobec","year":"2014","journal-title":"Nutrition"},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib539","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27224","volume":"65","author":"Trucco","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib540","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaoncol.2021.2328","article-title":"Metformin in combination with chemoradiotherapy in locally advanced non\u2013small cell lung cancer: the OCOG-ALMERA randomized clinical trial","volume":"7","author":"Tsakiridis","year":"2021","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib541","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053096","article-title":"Thyroid cancer risk is not increased in diabetic patients","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib543","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.18632\/oncotarget.6626","article-title":"Metformin may reduce oral cancer risk in patients with type 2 diabetes","volume":"7","author":"Tseng","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib545","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.18632\/oncotarget.13824","article-title":"Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus","volume":"8","author":"Tseng","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib546","article-title":"Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes","volume":"8","author":"Tseng","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib547","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clbc.2016.11.002","article-title":"Sitagliptin may reduce breast cancer risk in women with type 2 diabetes","volume":"17","author":"Tseng","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.mam.2026.101521_bib548","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1185053","article-title":"Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients","volume":"14","author":"Tseng","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib542","article-title":"Thyroid cancer risk is not increased in diabetic patients","volume":"7","author":"Tseng","year":"2012"},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib544","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/dmrr.2649","article-title":"Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus","volume":"31","author":"Tseng","year":"2015","journal-title":"Diabetes Metabol. Res. Rev."},{"key":"10.1016\/j.mam.2026.101521_bib549","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2021.08.006","article-title":"Metformin inhibits gastric cancer cell proliferation by regulation of a novel Loc100506691-CHAC1 axis","volume":"22","author":"Tseng","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib550","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1002\/jcp.26225","article-title":"Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPAR\u03b3-independent pathway","volume":"233","author":"Tsubaki","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib551","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1002\/jcp.26225","article-title":"Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPAR\u03b3\u2010independent pathway","volume":"233","author":"Tsubaki","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib552","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.2337\/dc15-1358","article-title":"The use of glyburide compared with other sulfonylureas and the risk of cancer in patients with type 2 diabetes","volume":"38","author":"Tuccori","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mam.2026.101521_bib553","article-title":"An in-vitro and in Silico anticancer study of FDA approved antidiabetic drugs glimepiride and empagliflozin","volume":"10","author":"Uzma","year":"2020","journal-title":"Int. J. Pharma Bio Sci."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib554","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1210\/en.2014-1717","article-title":"Effects of dulaglutide on thyroid C cells and serum calcitonin in male monkeys","volume":"156","author":"Vahle","year":"2015","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib555","article-title":"Metformin improves cancer immunotherapy by directly rescuing tumor-infiltratingCD8Tlymphocytes from hypoxia-induced immunosuppression","volume":"11","author":"Van Meerbeeck","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"5930","key":"10.1016\/j.mam.2026.101521_bib556","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib557","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/iub.2454","article-title":"The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities","volume":"73","author":"Varela\u2010Calvi\u00f1o","year":"2021","journal-title":"IUBMB Life"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib558","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/app15041925","article-title":"Therapeutic potential and challenges of pioglitazone in cancer treatment","volume":"15","author":"Vasileiou","year":"2025","journal-title":"Appl. Sci."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib559","doi-asserted-by":"crossref","first-page":"967","DOI":"10.36740\/WLek202005124","article-title":"Cancer of the organs of the reproductive system in women with type 2 diabetes. effects of antidiabetic therapy","volume":"73","author":"Vatseba","year":"2020","journal-title":"Wiad. Lek."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib560","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2174\/1573399816666200206112318","article-title":"Reducing the burden of diabetes treatment: a review of low-cost oral hypoglycemic medications","volume":"16","author":"Vaughan","year":"2020","journal-title":"Curr. Diabetes Rev."},{"issue":"32","key":"10.1016\/j.mam.2026.101521_bib561","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.9843","article-title":"Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport","volume":"7","author":"Velez","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib562","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/endrev\/bnad005","article-title":"Insulin\/IGF axis and the receptor for advanced glycation end products: role in meta-inflammation and potential in cancer therapy","volume":"44","author":"Vella","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mam.2026.101521_bib563","article-title":"Comparative study of in vitro anti-proliferative activity of metformin, teneligliptin, and canagliflozin against breast cancer cell line","author":"Venugopal","year":"2024","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib564","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib565","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metabol."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib566","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.mam.2026.101521_bib567","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.110803","article-title":"A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells","volume":"509","author":"Vitali","year":"2020","journal-title":"Mol. Cell. Endocrinol."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib578","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1111\/odi.14893","article-title":"Linagliptin's impact on lymphatic barrier and lymphangiogenesis in oral cancer with high glucose","volume":"30","author":"Wang","year":"2024","journal-title":"Oral Dis."},{"key":"10.1016\/j.mam.2026.101521_bib571","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopha.2016.06.047","article-title":"Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2\/M-phase arrest, independent of PPAR-\u03b3 pathway","volume":"83","author":"Wang","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib579","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10495-024-01944-7","article-title":"FAM83B regulates mitochondrial metabolism and anti-apoptotic activity in pulmonary adenocarcinoma","volume":"29","author":"Wang","year":"2024","journal-title":"Apoptosis"},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib580","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib575","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41389-021-00364-5","article-title":"Fatty acid transport protein-5 (FATP5) deficiency enhances hepatocellular carcinoma progression and metastasis by reprogramming cellular energy metabolism and regulating the AMPK-mTOR signaling pathway","volume":"10","author":"Wang","year":"2021","journal-title":"Oncogenesis"},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib573","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/cam4.3024","article-title":"Sitagliptin affects gastric cancer cells proliferation by suppressing melanoma\u2010associated antigen\u2010A3 expression through yes\u2010associated protein inactivation","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib568","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11864-024-01179-3","article-title":"Research progress on the use of metformin in leukemia treatment","volume":"25","author":"Wang","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib569","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11864-024-01179-3","article-title":"Research progress on the use of metformin in leukemia treatment","volume":"25","author":"Wang","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib577","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/HEP.0000000000000025","article-title":"SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment","volume":"78","author":"Wang","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib570","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1476-4598-10-56","article-title":"Natriuretic peptide receptor a as a novel target for prostate cancer","volume":"10","author":"Wang","year":"2011","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib572","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/icb.2016.116","article-title":"The pro\u2010fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride\u2010induced experimental liver injury","volume":"95","author":"Wang","year":"2017","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib576","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12935-022-02496-z","article-title":"SGLT2 inhibition restrains thyroid cancer growth via G1\/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways","volume":"22","author":"Wang","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.mam.2026.101521_bib574","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00280-019-04025-8","article-title":"Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib","volume":"85","author":"Wang","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"S1","key":"10.1016\/j.mam.2026.101521_bib581","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2019.33.1_supplement.647.48","article-title":"The effect of sodium glucose transporter 2 inhibitors on proliferation and growth factor signaling pathways in triple negative breast cancer","volume":"33","author":"Ware","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.mam.2026.101521_bib582","volume":"8","author":"Wariyapperuma","year":"2020"},{"key":"10.1016\/j.mam.2026.101521_bib585","doi-asserted-by":"crossref","DOI":"10.1016\/j.archoralbio.2020.104971","article-title":"Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor","volume":"121","author":"Wei","year":"2021","journal-title":"Arch. Oral Biol."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib583","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cbin.10925","article-title":"Anti-proliferative effect of rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells","volume":"42","author":"Wei","year":"2018","journal-title":"Cell Biol. Int."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib584","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cbin.10925","article-title":"Anti\u2010proliferative effect of rosiglitazone in the human t\u2010lymphocyte leukaemia cell line Jurkat cells","volume":"42","author":"Wei","year":"2018","journal-title":"Cell Biol. Int."},{"issue":"14","key":"10.1016\/j.mam.2026.101521_bib586","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mam.2026.101521_bib587","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2017.09.012","article-title":"Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia","volume":"57","author":"Willmann","year":"2018","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.mam.2026.101521_bib588","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2017.09.012","article-title":"Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph(+) chronic myeloid leukemia","volume":"57","author":"Willmann","year":"2018","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib589","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030487","article-title":"DPP4 Inhibitor sitagliptin enhances lymphocyte recruitment and prolongs survival in a syngeneic ovarian cancer mouse model","volume":"13","author":"Wilson","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib590","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/cancers13030487","article-title":"DPP4 inhibitor sitagliptin enhances lymphocyte recruitment and prolongs survival in a syngeneic ovarian cancer mouse model","volume":"13","author":"Wilson","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib591","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.radonc.2016.01.012","article-title":"Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy","volume":"118","author":"Wink","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib592","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib595","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12672-023-00719-x","article-title":"Empagliflozin: a potential anticancer drug","volume":"14","author":"Wu","year":"2023","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib596","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12672-023-00719-x","article-title":"Empagliflozin: a potential anticancer drug","volume":"14","author":"Wu","year":"2023","journal-title":"Discov. Oncol."},{"issue":"44","key":"10.1016\/j.mam.2026.101521_bib597","doi-asserted-by":"crossref","first-page":"50821","DOI":"10.1021\/acsami.3c10940","article-title":"Endoplasmic reticulum-targeted aggregation-induced emission luminogen for synergetic tumor ablation with glibenclamide","volume":"15","author":"Wu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib593","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1021\/acsomega.9b04357","article-title":"Anticancer effect of rosiglitazone, a PPAR-\u03b3 agonist against diethylnitrosamine-induced lung carcinogenesis","volume":"5","author":"Wu","year":"2020","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib594","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12079-021-00648-w","article-title":"Targeting of the tumor immune microenvironment by metformin","volume":"16","author":"Wu","year":"2022","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.mam.2026.101521_bib598","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2018.04.027","article-title":"Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1\/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells","volume":"830","author":"Xia","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib600","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13046-020-01627-6","article-title":"Metformin inhibits cervical cancer cell proliferation by modulating PI3K\/Akt-induced major histocompatibility complex class I-related chain A gene expression","volume":"39","author":"Xia","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib599","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1159\/000488183","article-title":"Pioglitazone confers neuroprotection against ischemia-induced pyroptosis due to its inhibitory effects on HMGB-1\/RAGE and Rac1\/ROS pathway by activating PPAR-\u0264","volume":"45","author":"Xia","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.mam.2026.101521_bib603","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2024.01.007","article-title":"Associations of metformin therapy treatment with endometrial cancer risk and prognosis: a systematic review and meta-analysis","volume":"182","author":"Xie","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mam.2026.101521_bib601","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2020.09.005","article-title":"An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells","volume":"495","author":"Xie","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mam.2026.101521_bib602","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2020.09.005","article-title":"An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells","volume":"495","author":"Xie","year":"2020","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib604","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","article-title":"Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma","volume":"72","author":"Xiong","year":"2023","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib608","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s40618-024-02351-0","article-title":"Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis","volume":"47","author":"Xu","year":"2024","journal-title":"J. Endocrinol. Investig."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib609","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s40618-024-02351-0","article-title":"Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis","volume":"47","author":"Xu","year":"2024","journal-title":"J. Endocrinol. Investig."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib606","first-page":"1223","article-title":"Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter-1 and lactate dehydrogenase A","volume":"57","author":"Xu","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib607","first-page":"1223","article-title":"Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter-1 and lactate dehydrogenase A","volume":"57","author":"Xu","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib605","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12957-018-1362-1","article-title":"Prognostic value of metformin for non-small cell lung cancer patients with diabetes","volume":"16","author":"Xu","year":"2018","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib610","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21873\/anticanres.13933","article-title":"Metformin inhibits proliferation and tumor growth of QGP-1 pancreatic neuroendocrine tumor cells by inducing cell cycle arrest and apoptosis","volume":"40","author":"Yamana","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.mam.2026.101521_bib611","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.2147\/OTT.S259853","article-title":"Inactivation of pancreatic stellate cells by Exendin-4 inhibits the migration and invasion of pancreatic cancer cells","volume":"13","author":"Yan","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.mam.2026.101521_bib612","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.2147\/OTT.S259853","article-title":"Inactivation of pancreatic stellate cells by exendin-4 inhibits the migration and invasion of pancreatic cancer cells","volume":"13","author":"Yan","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.mam.2026.101521_bib618","article-title":"Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib616","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/0008-5472.CAN-18-0620","article-title":"Inhibition of dipeptidyl peptidase-4 accelerates epithelial\u2013mesenchymal transition and breast cancer metastasis via the CXCL12\/CXCR4\/mTOR axis","volume":"79","author":"Yang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2026.101521_bib620","series-title":"Potassium in Health and Disease-Nutrition and Transport Mechanisms","article-title":"ATP-sensitive potassium channel","author":"Yang","year":"2024"},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib613","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/17512433.2018.1503051","article-title":"Ertugliflozin for treatment of patients with Type 2 diabetes mellitus","volume":"11","author":"Yang","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib621","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.4722","article-title":"GLP-1 receptor agonists and noncardiometabolic outcomes: an umbrella review of meta-analyses","volume":"9","author":"Yang","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.mam.2026.101521_bib617","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211027819","article-title":"Metformin antagonizes ovarian cancer cells malignancy through MSLN mediated IL-6\/STAT3 signaling","volume":"30","author":"Yang","year":"2021","journal-title":"Cell Transplant."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib614","doi-asserted-by":"crossref","first-page":"8679","DOI":"10.18632\/oncotarget.14412","article-title":"DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib615","doi-asserted-by":"crossref","first-page":"8679","DOI":"10.18632\/oncotarget.14412","article-title":"DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mam.2026.101521_bib619","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mam.2026.101521_bib623","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.942380","article-title":"Association between metformin use and the risk, prognosis of gynecologic cancer","volume":"12","author":"Yao","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib622","article-title":"Metformin use and lung cancer risk in diabetic patients: a systematic review and meta\u2010analysis","volume":"2019","author":"Yao","year":"2019","journal-title":"Dis. Markers"},{"issue":"3","key":"10.1016\/j.mam.2026.101521_bib624","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ygyno.2011.02.021","article-title":"Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins","volume":"121","author":"Yasmeen","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib625","doi-asserted-by":"crossref","first-page":"H1454","DOI":"10.1152\/ajpheart.00867.2009","article-title":"The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA","volume":"298","author":"Ye","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib626","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-06-1947","article-title":"Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers","volume":"13","author":"Yee","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib627","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-06-1947","article-title":"Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers","volume":"13","author":"Yee","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2026.101521_bib628","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215582","article-title":"Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells","volume":"532","author":"You","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mam.2026.101521_bib629","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117276","article-title":"Inhibition of mTORC1\/P70S6K pathway by metformin synergistically sensitizes acute myeloid leukemia to Ara-C","volume":"243","author":"Yuan","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib630","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9390878","article-title":"Role of Wnt\/\u03b2\u2010catenin signaling in the chemoresistance modulation of colorectal cancer","volume":"2020","author":"Yuan","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.mam.2026.101521_bib631","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154640","article-title":"Exploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activity","volume":"248","author":"Yurttas","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.mam.2026.101521_bib632","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102511","article-title":"Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes","volume":"16","author":"Zaazouee","year":"2022","journal-title":"Diabetes Metabol. Syndr.: Clin. Res. Rev."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib633","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.4071","article-title":"Effects of metformin on cancers in experimental and clinical studies: focusing on autophagy and AMPK\/mTOR signaling pathways","volume":"42","author":"Zamanian","year":"2024","journal-title":"Cell Biochem. Funct."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib634","article-title":"The effects of 6 common antidiabetic drugs on anti\u2010PD1 immune checkpoint inhibitor in tumor treatment","volume":"2022","author":"Zhan","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.mam.2026.101521_bib635","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2651790","article-title":"The effects of 6 common antidiabetic drugs on Anti-PD1 immune checkpoint inhibitor in tumor treatment","volume":"2022","author":"Zhan","year":"2022","journal-title":"J. Immunol. Res."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib637","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2009.03.012","article-title":"AMPK: an emerging drug target for diabetes and the metabolic syndrome","volume":"9","author":"Zhang","year":"2009","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib639","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/CAD.0000000000000236","article-title":"Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes","volume":"26","author":"Zhang","year":"2015","journal-title":"Anti Cancer Drugs"},{"issue":"7","key":"10.1016\/j.mam.2026.101521_bib640","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/CAD.0000000000000236","article-title":"Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes","volume":"26","author":"Zhang","year":"2015","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.mam.2026.101521_bib645","article-title":"Glimepiride overcomes acquired resistance to EGFR TKIs in lung cancer via the AMPK\/ERK\/MMP7 signaling pathway","author":"Zhang","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib636","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4161\/cbt.5.8.2887","article-title":"PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404","volume":"5","author":"Zhang","year":"2006","journal-title":"Cancer Biol. Ther."},{"issue":"14","key":"10.1016\/j.mam.2026.101521_bib642","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14715\/cmb\/2023.69.14.37","article-title":"GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells","volume":"69","author":"Zhang","year":"2023","journal-title":"Cell. Mol. Biol."},{"issue":"14","key":"10.1016\/j.mam.2026.101521_bib643","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14715\/cmb\/2023.69.14.37","article-title":"GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells","volume":"69","author":"Zhang","year":"2023","journal-title":"Cell. Mol. Biol. (Noisy-Le-Grand)"},{"issue":"8","key":"10.1016\/j.mam.2026.101521_bib641","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/cam4.1133","article-title":"Metformin synergistic pemetrexed suppresses non\u2010small\u2010cell lung cancer cell proliferation and invasion in vitro","volume":"6","author":"Zhang","year":"2017","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101521_bib644","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12935-024-03516-w","article-title":"Non-coding RNAs as potential targets in metformin therapy for cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"19","key":"10.1016\/j.mam.2026.101521_bib646","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202411980","article-title":"The novel dual GIP and GLP\u20101 receptor agonist tirzepatide attenuates Colon cancer development by regulating glucose metabolism","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"issue":"10","key":"10.1016\/j.mam.2026.101521_bib638","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2337\/dc11-0512","article-title":"Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis","volume":"34","author":"Zhang","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mam.2026.101521_bib653","article-title":"Sulfonylurea and cancer risk among patients with type 2 diabetes: a population-based cohort study","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.mam.2026.101521_bib647","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/dom.12291","article-title":"Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/Akt pathway","volume":"16","author":"Zhao","year":"2014","journal-title":"Diabetes Obes. Metabol."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib648","doi-asserted-by":"crossref","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","article-title":"Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner","volume":"306","author":"Zhao","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"issue":"12","key":"10.1016\/j.mam.2026.101521_bib649","doi-asserted-by":"crossref","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","article-title":"Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner","volume":"306","author":"Zhao","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.mam.2026.101521_bib650","first-page":"5202","article-title":"Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression","volume":"17","author":"Zhao","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.mam.2026.101521_bib651","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.mam.2026.101521_bib652","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.mam.2026.101521_bib654","first-page":"1","article-title":"Liposomal vardenafil and linagliptin combined with irinotecan for synergistic colorectal cancer therapy","author":"Zhao","year":"2025","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib655","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1111\/cas.15524","article-title":"Metformin inhibits the proliferation and invasion of ovarian cancer cells by suppressing tripartite motif\u2010containing 37\u2010induced tumor necrosis factor receptor\u2010associated factor 2 ubiquitination","volume":"113","author":"Zheng","year":"2022","journal-title":"Cancer Sci."},{"issue":"22","key":"10.1016\/j.mam.2026.101521_bib659","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.7150\/jca.60208","article-title":"Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia","volume":"12","author":"Zhou","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.mam.2026.101521_bib658","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"29","key":"10.1016\/j.mam.2026.101521_bib657","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1038\/onc.2017.38","article-title":"The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP\u2013PKA\u2013EGFR\u2013STAT3 axis","volume":"36","author":"Zhou","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.mam.2026.101521_bib656","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.15099","article-title":"Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator","volume":"5","author":"Zhou","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.mam.2026.101521_bib661","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1387243","article-title":"Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.mam.2026.101521_bib660","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/CM9.0000000000001363","article-title":"Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5\u2032-monophosphate (AMP)-activated protein kinase signaling pathway","volume":"134","author":"Zhu","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.mam.2026.101521_bib662","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fonc.2017.00243","article-title":"Metformin: a bridge between diabetes and prostate cancer","volume":"7","author":"Zingales","year":"2017","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.mam.2026.101521_bib663","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.mam.2026.101521_bib664","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1007\/s12094-023-03187-5","article-title":"Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer","volume":"25","author":"Zuo","year":"2023","journal-title":"Clin. Transl. Oncol."}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299726000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299726000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:26:20Z","timestamp":1792092380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299726000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":663,"alternative-id":["S0098299726000774"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2026.101521","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2026.101521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101521"}}